Astrazeneca PLC 6-K, filed Apr 25, 2024
Astrazeneca PLC (AZN)
6-K
2024-04-25
For: 2024-04-25
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on April 25, 2024.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
1st Quarter Results
AstraZeneca
25 April 2024
Q1 2024 results
Very strong revenue and EPS growth in the first quarter coupled
with exciting pipeline delivery
Revenue and EPS summary
|
|
|
Q1 2024
|
% Change
|
|||||
|
|
|
$m
|
Actual
|
CER[1]
|
|
|||
|
-
Product Sales
|
|
12,177
|
15
|
18
|
|
|||
|
-
Alliance Revenue
|
|
457
|
59
|
59
|
|
|||
|
-
Collaboration Revenue
|
|
45
|
66
|
66
|
|
|||
|
Total
Revenue
|
|
12,679
|
17
|
19
|
|
|||
|
Reported
EPS
|
|
$1.41
|
21
|
30
|
|
|||
|
|
$2.06
|
7
|
13
|
|
||||
|
|
|
|
|
|
|
|
|
|
Financial performance for Q1
2024 (Growth numbers at CER)
‒ Total
Revenue up 19% to $12,679m, driven by an 18% increase in Product
Sales and continued growth in Alliance Revenue from partnered
medicines
‒ Double-digit
growth in Total Revenue from Oncology at 26%, CVRM at 23%, R&I
at 17%, and Rare Disease at 16%.
‒ Core
Product Sales Gross Margin[3] of
82%
‒ Core
Operating Margin of 34%
‒ Core
Tax Rate of 21%
‒ Core
EPS increased 13% to $2.06. The increase in Core EPS was lower than
Total Revenue growth principally due to a $241m gain in the prior
year period on the disposal of Pulmicort
Flexhaler US
rights
‒ As
announced at the Annual General Meeting on 11 April 2024, the total
dividend for FY 2024 will increase by $0.20 per share to $3.10 per
share
‒ Total
Revenue and Core EPS guidance at CER for FY 2024
reiterated
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
"AstraZeneca had a very strong start in 2024 with substantial Total
Revenue growth of 19% in the first quarter.
Our strong pipeline momentum continued and already this year we
announced positive trial results for Imfinzi and Tagrisso that were
unprecedented in lung cancer, the data from both of these studies
will be presented during the ASCO plenary in June. We are
also looking forward to seeing the results of several other
important trials throughout the year.
At our Annual General Meeting we were pleased to announce a 7%
increase in the annual dividend, and at our Investor Day on 21 May
2024 we will outline the evolution of our company, underscoring our
confidence in sustaining industry-leading growth."
Key milestones achieved since the prior results
announcement
‒ Positive
read-outs for Tagrisso in unresectable, Stage
III EGFRm NSCLC (LAURA), Imfinzi in LS-SCLC (ADRIATIC)
‒ US
approvals for Tagrisso with the addition of chemotherapy
for EGFRm NSCLC (FLAURA2), Enhertu in HER2-positive solid tumours
(DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02)
and Ultomiris for NMOSD. US and EU approval
for Voydeya as an add-on
therapy to Ultomiris or Soliris for PNH with EVH (ALPHA). Japan approval
for Truqap plus Faslodex in unresectable or
recurrent PIK3CA-, AKT1-, or PTEN-altered HR-positive, HER2-negative breast cancer
(CAPItello-291).
‒ Datopotamab
deruxtecan BLAs accepted in the US for non-squamous NSCLC
(TROPION-Lung01) and HR-positive, HER2-negative breast cancer
(TROPION-Breast01).
Guidance
The Company reiterates its Total Revenue and Core EPS guidance for
FY 2024 at CER, based on the average foreign exchange rates through
2023.
Total Revenue is expected to increase by a low double-digit to
low teens percentage
Core EPS is expected to increase by a low double-digit to low
teens percentage
‒ Collaboration
Revenue is expected to increase substantially, driven by
success-based milestones and certain anticipated
transactions
‒ Other
operating income is expected to decrease substantially (FY 2023
included a $241m gain on the disposal of Pulmicort
Flexhaler US rights, and a
$712m one-time gain relating to updates to contractual arrangements
for Beyfortus)
‒ The
Core Tax rate is expected to be between 18-22%
The Company is unable to provide guidance on a Reported basis
because it cannot reliably forecast material elements of the
Reported results, including any fair value adjustments arising on
acquisition-related liabilities, intangible asset impairment
charges and legal settlement provisions. Please refer to the
cautionary statements section regarding forward-looking statements
at the end of this announcement.
Currency impact
If foreign exchange rates for April 2024 to December 2024 were to
remain at the average rates seen in March 2024, compared to the
performance at CER it is anticipated that FY 2024 Total Revenue
would incur a low single-digit adverse impact and Core EPS would
incur a mid single-digit adverse impact (previously low
single-digit). The Company's foreign exchange rate sensitivity
analysis is provided in Table 16.
Investor Day
AstraZeneca will host an Investor Day on 21 May 2024. For more
information, see www.astrazeneca.com/investor-relations.html.
Table 1: Key
elements of Total Revenue performance in Q1
2024
|
|
% Change
|
|
|
|
Revenue type
|
|
$m
|
Actual %
|
CER %
|
|
|
|
Product Sales
|
|
12,177
|
15
|
18
|
|
|
|
Alliance Revenue
|
|
457
|
59
|
59
|
|
∗
$339m Enhertu (Q1 2023:
$220m)
∗
$77m Tezspire (Q1 2023:
$43m)
|
|
Collaboration Revenue
|
|
45
|
66
|
66
|
|
∗
$45m Farxiga (Q1 2023:
$24m)
|
|
Total Revenue
|
|
12,679
|
17
|
19
|
|
|
|
Therapy areas
|
|
$m
|
Actual %
|
CER %
|
|
|
|
Oncology
|
|
5,108
|
23
|
26
|
|
∗ Strong
performance across all key medicines and regions
|
|
CVRM
|
|
3,060
|
20
|
23
|
|
∗ Farxiga up 43% (45% at CER) with
continued demand growth and the launch of an authorised generic in
the US, Lokelma up 16% (19% at CER),
roxadustat up 24% (28% at CER), Brilinta decreased 3% (1% at
CER)
|
|
R&I
|
|
1,886
|
15
|
17
|
|
∗ Continued strong
growth from Fasenra up 6% (6%
CER), Breztri up
52% (54% CER). Saphnelo up 94% (95% CER)
and Tezspire up
>2x (>2x CER). Symbicort was up 12% (14%
CER)
|
|
V&I
|
|
232
|
(35)
|
(34)
|
|
∗ Beyfortus revenue was $46m (Q1
2023: $nil), which more than offset a $27m decline
in Synagis
∗ The drop in
V&I revenue was driven by lower sales of COVID-19 mAbs
and Vaxzevria.
Vaxzevria revenues are now included in the 'Other'
V&I line
|
|
Rare Disease
|
|
2,096
|
12
|
16
|
|
∗ Ultomiris up 32% (34% at CER),
partially offset by decline in Soliris of 11% (8% at
CER)
∗ Strensiq up 20% (21% at CER)
and Koselugo up
68% (82% at CER) reflecting strong patient demand, and also tender
market order timing
|
|
Other Medicines
|
|
297
|
(7)
|
-
|
|
|
|
Total Revenue
|
|
12,679
|
17
|
19
|
|
|
|
Regions
|
|
$m
|
Actual %
|
CER %
|
|
|
|
US
|
|
5,124
|
19
|
19
|
|
|
|
Emerging Markets
|
|
3,732
|
18
|
26
|
|
|
|
- China
|
|
1,748
|
9
|
13
|
|
|
|
- Ex-China Emerging Markets
|
|
1,984
|
27
|
40
|
|
|
|
Europe
|
|
2,634
|
22
|
19
|
|
|
|
Established RoW
|
|
1,189
|
(5)
|
2
|
|
∗ Decline in
COVID-19 mAbs revenue
|
|
Total Revenue
|
|
12,679
|
17
|
19
|
|
|
Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited
(Daiichi Sankyo) and AstraZeneca, amounted to $879m in Q1 2024 (Q1
2023: $531m).
Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to
$216m in Q1 2024 (Q1 2023: $105m).
Table 2: Key
elements of financial performance in Q1 2024
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments[4]
|
|
Total Revenue
|
$12,679m
|
17% Actual 19% CER
|
$12,679m
|
17% Actual 19% CER
|
|
∗ See Table 1 and the Total Revenue section of this
document for further details
|
|
Product Sales Gross Margin
|
82%
|
Stable
|
82%
|
-1pp Actual -1pp CER
|
|
∗ Variations in Product Sales Gross Margin can be
expected between periods due to product seasonality, foreign
exchange fluctuations and other effects
|
|
R&D expense
|
$2,783m
|
7% Actual 7% CER
|
$2,698m
|
17% Actual 18% CER
|
|
+
Increased investment in the pipeline
∗ Core R&D-to-Total Revenue ratio of 21%(Q1
2023: 21%)
|
|
SG&A expense
|
$4,495m
|
11% Actual 12% CER
|
$3,413m
|
12% Actual 13% CER
|
|
+
Market development for recent launches and pre-launch
activities
∗ Core SG&A-to-Total Revenue ratio of 27%(Q1
2023: 28%)
|
|
Other operating income and expense[5]
|
$67m
|
-83% Actual -83% CER
|
$65m
|
-80% Actual -80% CER
|
|
‒ The
prior year quarter included a $241m gain on the disposal
of Pulmicort Flexhaler US rights
|
|
Operating Margin
|
25%
|
+1pp Actual +2pp CER
|
34%
|
-2pp Actual -1pp CER
|
|
∗ See commentary above on Other operating income and
expense
|
|
Net finance expense
|
$302m
|
5% Actual 1% CER
|
$245m
|
2% Actual -3% CER
|
|
+
Higher rates on floating debt and bond issuances
‒ Higher
interest received on cash and short-term
investments
|
|
Tax rate
|
22%
|
+2pp Actual +2pp CER
|
21%
|
+2pp Actual +2pp CER
|
|
∗ Variations in
the tax rate can be expected between periods
|
|
EPS
|
$1.41
|
21% Actual 30% CER
|
$2.06
|
7% Actual 13% CER
|
|
∗ Further details of differences between Reported
and Core are shown in Table 11
|
Table 3:
Pipeline highlights since prior results
announcement
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
|
Regulatory approvals and other regulatory actions
|
Enhertu
|
HER2-expressing tumours (DESTINY-PanTumor02)
|
Regulatory approval (US)
|
|
Tagrisso
|
EGFRm NSCLC (1st-line) (FLAURA2)
|
Regulatory approval (US)
|
|
|
Truqap
|
HR+/HER2-neg breast cancer (2nd-line) (CAPItello-291)
|
Regulatory approval (JP)
|
|
|
Beyfortus
|
RSV (MELODY-MEDLEY)
|
Regulatory approval (JP)
|
|
|
Ultomiris
|
NMOSD (CHAMPION-NMOSD)
|
Regulatory approval (US)
|
|
|
Voydeya
|
PNH with EVH (ALPHA)
|
Regulatory approval (US, EU)
|
|
|
|
|
|
|
|
Regulatory submissionsor acceptances*
|
Dato-DXd
|
Non-squamous NSCLC (2nd- and 3rd-line)
(TROPION-Lung01)
|
Regulatory submission (US)
|
|
Dato-DXd
|
HR+/HER2- breast cancer (inoperable and/or met.)
(TROPION-Breast01)
|
Regulatory submission (US, EU, JP, CN)
|
|
|
acoramidis
|
ATTR-CM (ALXN2060-TAC-302)
|
Regulatory submission (JP)
|
|
|
|
|
|
|
|
Major Phase III data readouts and other developments
|
Tagrisso
|
EGFRm NSCLC (unresectable Stg. III) (LAURA)
|
Primary endpoint met
|
|
Imfinzi
|
SCLC (limited-stage) (ADRIATIC)
|
Primary endpoint met
|
*US, EU and China regulatory submission denotes filing
acceptance
Upcoming pipeline catalysts
For recent trial starts and anticipated timings of key trial
readouts, please refer to the Clinical Trials Appendix, available
on www.astrazeneca.com/investor-relations.html.
Corporate and business development
In February 2024, AstraZeneca completed the acquisition of Gracell
Biotechnologies, Inc. (Gracell), a global clinical-stage
biopharmaceutical company developing innovative cell therapies for
the treatment of cancer and autoimmune diseases. The acquisition
enriches AstraZeneca's growing pipeline of cell therapies with
AZD0120 (formerly GC012F), a novel, clinical-stage T-cell (CAR-T)
therapy. AZD0120 is a potential new treatment for multiple myeloma,
as well as other haematologic malignancies and autoimmune diseases,
including SLE. The upfront cash portion of the consideration was
approximately $1.0 billion. Combined, the upfront and potential
contingent value payments represent, if achieved, a transaction
value of approximately $1.2 billion. AstraZeneca acquired the cash
and cash equivalents on Gracell's balance sheet, which totalled
$209 million at the close of the transaction.
In February 2024, AstraZeneca completed the acquisition of
Icosavax, Inc., a US-based clinical-stage biopharmaceutical company
focused on developing differentiated, high-potential vaccines using
an innovative, protein virus-like particle platform. The upfront
cash portion of the consideration was approximately $0.8 billion.
Combined, the upfront and maximum potential contingent value
payments represent, if achieved, a transaction value of
approximately $1.1 billion. AstraZeneca acquired the cash, cash
equivalents and marketable securities on Icosavax's balance sheet,
which totalled $192 million at the close of the
transaction.
In March 2024, AstraZeneca announced that it has entered into a
definitive agreement to acquire Amolyt Pharma, a clinical-stage
biotechnology company focused on developing novel treatments for
rare endocrine diseases. The proposed acquisition will bolster the
Rare Disease late-stage pipeline and expand on its bone metabolism
franchise with the notable addition of eneboparatide (AZP-3601), a
Phase III investigational therapeutic peptide with a novel
mechanism of action designed to meet key therapeutic goals for
hypoparathyroidism. The upfront cash portion of the consideration
is $0.8 billion at deal closing. Combined, the upfront and maximum
potential contingent value payments represent, if achieved, a
transaction value of $1.05 billion. AstraZeneca will acquire all of
Amolyt Pharma's outstanding shares on a cash and debt free basis.
Subject to the satisfaction of customary closing conditions in the
acquisition agreement, including regulatory clearances, the
transaction is expected to close by the end of the third quarter of
2024.
In March 2024, AstraZeneca entered into a definitive agreement to
acquire Fusion Pharmaceuticals Inc., a clinical-stage
biopharmaceutical company developing next-generation
radioconjugates. This complements AstraZeneca's leading oncology
portfolio with the addition of the Fusion pipeline of RCs,
including their most advanced programme, FPI-2265, a potential new
treatment for patients with mCRPC. The acquisition marks a major
step forward in AstraZeneca delivering on its ambition to transform
cancer treatment and outcomes for patients by replacing traditional
regimens like chemotherapy and radiotherapy with more targeted
treatments. The upfront cash portion of the consideration is
approximately $2 billion. Combined, the upfront and maximum
potential contingent value payments represent, if achieved, a
transaction value of approximately $2.4 billion. AstraZeneca will
acquire the cash, cash equivalents and short term investments on
Fusion's balance sheet, which totalled $234 million as of 31
December 2023. The transaction is expected to close in the
second quarter of 2024, subject to customary closing conditions,
including the approval of Fusion shareholders and regulatory
clearances.
Sustainability highlights
Our newly announced collaboration with China Resources Gas and
Everbright Environment will supply biomethane and biomethane-based
steam to our Wuxi site. Using domestic waste, including food and
plant waste, this new partnership will enable us to reduce our
greenhouse gas emissions footprint by 80% in China.
AstraZeneca announced at WEF that it will be one of the inaugural
Early Adopter organisations that intend to start making disclosures
aligned with the Taskforce on Nature-related Financial Disclosures
Recommendations in corporate reporting.
AstraZeneca also hosted an annual Sustainability call for
shareholders, reiterating its continued commitment to deliver
across our pillars; Access to Healthcare, Environmental Protection
and Ethics and Transparency. A recording of the call and
accompanying materials are available on the AstraZeneca IR
website.
Conference call
A conference call and webcast for investors and analysts will begin
today, 25 April 2024, at 11:45 UK time. Details can be accessed
via astrazeneca.com.
Reporting calendar
The Company intends to publish its H1 and Q2 2024 results on 25
July 2024.
Operating and financial review
All narrative on growth and results in this section is based on
actual exchange rates, and financial figures are in US$ millions
($m), unless stated otherwise. Unless stated otherwise, the
performance shown in this announcement covers the three month
period to 31 March 2024 ('the quarter' or 'Q1 2024') compared to
the three month period to 31 March 2023 ('Q1 2023'). References to
'first quarter', 'second quarter', 'third quarter' and fourth
quarter' refer to the respective quarters in FY 2024.
Core financial measures, EBITDA, Net debt, Product Sales Gross
Margin, Operating Margin and CER are non-GAAP financial measures
because they cannot be derived directly from the Group's Condensed
consolidated financial statements. Management believes that these
non-GAAP financial measures, when provided in combination with
Reported results, provide investors and analysts with helpful
supplementary information to understand better the financial
performance and position of the Group on a comparable basis from
period to period. These non-GAAP financial measures are not a
substitute for, or superior to, financial measures prepared in
accordance with GAAP.
Core financial measures are adjusted to exclude certain significant
items:
‒ Charges
and provisions related to restructuring programmes, which includes
charges that relate to the impact of restructuring programmes on
capitalised IT assets
‒ Amortisation
and impairment of intangible assets, including impairment reversals
but excluding any charges relating to IT assets
‒ Other
specified items, principally the imputed finance charges and fair
value movements relating to contingent consideration on business
combinations, imputed finance charges and remeasurement adjustments
on certain Other payables arising from intangible asset
acquisitions, legal settlements and remeasurement adjustments
relating to Other payables assumed from the Alexion
acquisition
‒ The
tax effects of the adjustments above are excluded from the Core Tax
charge
Details on the nature of Core financial measures are provided on
page 61 of the Annual Report and Form
20-F Information 2023.
Reference should be made to the Reconciliation of Reported to Core
financial measures table included in the financial performance
section in this announcement.
Product Sales Gross Margin is calculated by dividing the difference
between Product Sales and Cost of Sales by the Product
Sales. The calculation of
Reported and Core Product Sales Gross Margin excludes the impact of
Alliance Revenue and Collaboration Revenue and any associated
costs, thereby reflecting the underlying performance of Product
Sales.
EBITDA is defined as Reported Profit before tax after adding back
Net finance expense, results from Joint ventures and associates and
charges for Depreciation, amortisation and impairment. Reference
should be made to the Reconciliation of Reported Profit before tax
to EBITDA included in the financial performance section in this
announcement.
Operating margin is defined as Operating profit as a percentage of
Total Revenue.
Net debt is defined as Interest-bearing loans and borrowings and
Lease liabilities, net of Cash and cash equivalents, Other
investments, and Net derivative financial instruments. Reference
should be made to Note 3 'Net debt' included in the Notes to the
Interim financial statements in this announcement.
The Company strongly encourages investors and analysts not to rely
on any single financial measure, but to review AstraZeneca's
financial statements, including the Notes thereto, and other
available Company reports, carefully and in their
entirety.
Due to rounding, the sum of a number of dollar values and
percentages in this announcement may not agree to
totals.
Total Revenue
Table 4: Total
Revenue by therapy area and medicine[6]
|
|
|
Q1 2024
|
||
|
|
|
|
|
% Change
|
|
Total Revenue
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
5,108
|
40
|
23
|
26
|
|
- Tagrisso
|
|
1,595
|
13
|
12
|
15
|
|
- Imfinzi
|
|
1,113
|
9
|
29
|
33
|
|
- Calquence
|
|
718
|
6
|
35
|
35
|
|
- Lynparza
|
|
705
|
6
|
8
|
11
|
|
- Enhertu
|
|
461
|
4
|
79
|
79
|
|
- Zoladex
|
|
285
|
2
|
21
|
28
|
|
- Imjudo
|
|
62
|
-
|
66
|
70
|
|
- Truqap
|
|
50
|
-
|
n/m
|
n/m
|
|
- Orpathys
|
|
12
|
-
|
43
|
49
|
|
-
Other Oncology
|
|
107
|
1
|
(24)
|
(19)
|
|
BioPharmaceuticals: CVRM
|
|
3,060
|
24
|
20
|
23
|
|
- Farxiga
|
|
1,892
|
15
|
43
|
45
|
|
- Brilinta
|
|
323
|
3
|
(3)
|
(1)
|
|
- Crestor
|
|
297
|
2
|
(3)
|
2
|
|
- Seloken/Toprol-XL
|
|
165
|
1
|
(8)
|
(2)
|
|
- Lokelma
|
|
114
|
1
|
16
|
19
|
|
-
roxadustat
|
|
77
|
1
|
24
|
28
|
|
- Andexxa
|
|
47
|
-
|
6
|
6
|
|
- Wainua
|
|
5
|
-
|
n/m
|
n/m
|
|
-
Other CVRM
|
|
141
|
1
|
(33)
|
(31)
|
|
BioPharmaceuticals: R&I
|
|
1,886
|
15
|
15
|
17
|
|
- Symbicort
|
|
769
|
6
|
12
|
14
|
|
- Fasenra
|
|
358
|
3
|
6
|
6
|
|
- Pulmicort
|
|
224
|
2
|
1
|
5
|
|
- Breztri
|
|
219
|
2
|
52
|
54
|
|
- Tezspire
|
|
120
|
1
|
>2x
|
>2x
|
|
- Saphnelo
|
|
91
|
1
|
94
|
95
|
|
- Airsupra
|
|
7
|
-
|
n/m
|
n/m
|
|
-
Other R&I
|
|
98
|
1
|
(30)
|
(29)
|
|
BioPharmaceuticals: V&I
|
|
232
|
2
|
(35)
|
(34)
|
|
- Synagis
|
|
171
|
1
|
(13)
|
(13)
|
|
- Beyfortus
|
|
46
|
-
|
n/m
|
n/m
|
|
- FluMist
|
|
7
|
-
|
>2x
|
>2x
|
|
-
COVID-19 mAbs
|
|
2
|
-
|
(99)
|
(99)
|
|
-
Other V&I
|
|
6
|
-
|
(79)
|
(80)
|
|
Rare Disease
|
|
2,096
|
17
|
12
|
16
|
|
- Ultomiris
|
|
859
|
7
|
32
|
34
|
|
- Soliris
|
|
739
|
6
|
(11)
|
(8)
|
|
- Strensiq
|
|
313
|
2
|
20
|
21
|
|
- Koselugo
|
|
132
|
1
|
68
|
82
|
|
- Kanuma
|
|
53
|
-
|
32
|
35
|
|
Other Medicines
|
|
297
|
2
|
(7)
|
-
|
|
- Nexium
|
|
243
|
2
|
(2)
|
7
|
|
-
Others
|
|
54
|
-
|
(25)
|
(23)
|
|
Total Medicines
|
|
12,679
|
100
|
17
|
19
|
Table 5: Alliance Revenue
|
|
|
Q1 2024
|
|||
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Enhertu
|
|
339
|
74
|
54
|
54
|
|
Tezspire
|
|
77
|
17
|
80
|
80
|
|
Beyfortus
|
|
20
|
4
|
n/m
|
n/m
|
|
Other Alliance Revenue
|
|
21
|
5
|
(10)
|
(9)
|
|
Total
|
|
457
|
100
|
59
|
59
|
Table 6: Collaboration Revenue
|
|
|
Q1 2024
|
|||
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Farxiga: sales
milestones
|
|
45
|
100
|
86
|
86
|
|
Other Collaboration Revenue
|
|
-
|
-
|
n/m
|
n/m
|
|
Total
|
|
45
|
100
|
66
|
66
|
Table 7: Total
Revenue by therapy area
|
|
|
Q1 2024
|
||
|
|
|
|
|
% Change
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
5,108
|
40
|
23
|
26
|
|
Biopharmaceuticals
|
|
5,178
|
41
|
14
|
16
|
|
CVRM
|
|
3,060
|
24
|
20
|
23
|
|
R&I
|
|
1,886
|
15
|
15
|
17
|
|
V&I
|
|
232
|
2
|
(35)
|
(34)
|
|
Rare Disease
|
|
2,096
|
17
|
12
|
16
|
|
Other Medicines
|
|
297
|
2
|
(7)
|
-
|
|
Total
|
|
12,679
|
100
|
17
|
19
|
Table 8: Total
Revenue by region
|
|
|
Q1 2024
|
||
|
|
|
|
|
% Change
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
|
5,124
|
40
|
19
|
19
|
|
Emerging Markets
|
|
3,732
|
29
|
18
|
26
|
|
China
|
|
1,748
|
14
|
9
|
13
|
|
Emerging Markets ex. China
|
|
1,984
|
16
|
27
|
40
|
|
Europe
|
|
2,634
|
21
|
22
|
19
|
|
Established ROW
|
|
1,189
|
9
|
(5)
|
2
|
|
Total
|
|
12,679
|
100
|
17
|
19
|
Oncology
Oncology Total Revenue of $5,108m in Q1 2024 increased by 23% (26%
at CER), representing 40% of overall Total Revenue (Q1 2023: 38%).
Product Sales increased by 21% (24% at CER) in Q1 2024 to $4,760m,
reflecting new launches and expanded reimbursement across key
brands.
Tagrisso
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
1,595
|
|
623
|
488
|
302
|
182
|
|
Actual change
|
|
12%
|
|
20%
|
10%
|
18%
|
(10%)
|
|
CER change
|
|
15%
|
|
20%
|
17%
|
15%
|
(2%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Strong global demand for Tagrisso in adjuvant (ADAURA) and 1st -line setting
(FLAURA)
|
|
US
|
|
∗ Continued strong adjuvant and 1st-line demand
growth
|
|
Emerging Markets
|
|
∗ Encouraging demand growth across markets with some
positive impact of hospital ordering dynamics in
China
∗ Strong performance across Latin America and Asia
Pacific markets
|
|
Europe
|
|
∗ Continued growth in 1st-line setting and
increasing adjuvant demand
|
|
Established RoW
|
|
∗ Increased demand in adjuvant and 1st-line offset
by a 10.5% mandatory price reduction in Japan effective June
2023
|
Imfinzi
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
1,113
|
|
582
|
129
|
232
|
170
|
|
Actual change
|
|
29%
|
|
19%
|
59%
|
43%
|
31%
|
|
CER change
|
|
33%
|
|
19%
|
83%
|
40%
|
45%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Continued growth driven by BTC (TOPAZ-1), HCC
(HIMALAYA), and increased patient share in Stage IV NSCLC
(POSEIDON) and extensive-stage SCLC (CASPIAN)
|
|
US
|
|
∗ Continued demand growth driven by BTC, HCC, and
extensive-stage SCLC
∗ Growth in BTC slowing
with Imfinzi now
the clear standard-of-care
|
|
Emerging Markets
|
|
∗ Continued China growth driven by demand in
HCC
|
|
Europe
|
|
∗ Growth driven by share gains in extensive-stage
SCLC and new indications
|
|
Established RoW
|
|
∗ Increased demand from new
launches, offset by a 25%
mandatory price reduction in Japan effective 1 February
2024
|
Lynparza
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
705
|
|
288
|
167
|
191
|
59
|
|
Actual change
|
|
8%
|
|
7%
|
23%
|
7%
|
(13%)
|
|
CER change
|
|
11%
|
|
7%
|
33%
|
5%
|
(6%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Lynparza remains
the leading medicine in the PARP inhibitor class globally across
four tumour types (ovarian, breast, prostate, pancreatic), as
measured by total prescription volume
∗ No Collaboration Revenue
for Lynparza was recognised in either Q1 2024 or Q1 2023,
hence the Product Sales numbers are identical to the Total Revenue
numbers shown above
|
|
US
|
|
∗ Continued leadership within PARPi class despite
increasing competition, negative class pressure and maturity of the
market
|
|
Emerging Markets
|
|
∗ Demand growth in China coming from newly diagnosed
BRCA-mutated ovarian cancer (SOLO-1) and inclusion of HRD-positive
ovarian cancer (PAOLA-1) on NRDL with no price
reduction
|
|
Europe
|
|
∗ Demand growth driven by mCRPC (PROpel) and early
breast cancer (OlympiA)
|
|
Established RoW
|
|
∗ Demand growth coming from HRD-positive ovarian
cancer, partially offset by price reduction in Japan effective from
November 2023
|
Enhertu
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
461
|
|
202
|
112
|
134
|
13
|
|
Actual change
|
|
79%
|
|
26%
|
>2x
|
>2x
|
>3x
|
|
CER change
|
|
79%
|
|
26%
|
>2x
|
>2x
|
>3x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca,
amounted to $879m in Q1 2024 (Q1 2023:
$531m)
|
|
US
|
|
∗ US in-market sales, recorded by Daiichi Sankyo,
amounted to $423m in Q1 2024 (Q1 2023: $336m)
∗ Strong demand across launched
indications
|
|
Emerging Markets
|
|
∗ Strong uptake in China following HER2-positive
(DESTINY-Breast03) and HER2-low (DESTINY-Breast04)
launches
∗ Some launch-related inventory build was observed
in China in Q1 2024
|
|
Europe
|
|
∗ Continued growth driven by increasing adoption in
HER2-positive and HER2-low metastatic breast
cancer
|
|
Established RoW
|
|
∗ AstraZeneca's Alliance Revenue includes a mid
single-digit percentage royalty on Daiichi Sankyo's sales in
Japan
|
Calquence
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
718
|
|
494
|
39
|
153
|
32
|
|
Actual change
|
|
35%
|
|
29%
|
>2x
|
42%
|
44%
|
|
CER change
|
|
35%
|
|
29%
|
>2x
|
39%
|
47%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Sustained leadership in front-line CLL with
increased global penetration
|
|
US
|
|
∗ Continued market growth and maintaining leading
share of new CLL patient starts in the front
line
|
|
Europe
|
|
∗ Continued growth supported by launches in further
European markets
|
Other Oncology medicines
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Zoladex
|
|
285
|
21%
|
28%
|
∗ Strong underlying growth in China and Emerging
Markets and moderate growth in Europe offset by drop in
Japan
|
|
Imjudo
|
|
62
|
66%
|
70%
|
∗ Continued growth across markets slightly offset by
US inventory destocking in Q1 2024
|
|
Truqap
|
|
50
|
n/m
|
n/m
|
∗ Rapid adoption following US approval in November
2023 for HR-positive HER2-negative metastatic breast cancer with
one or more biomarker alterations
(CAPItello-291)
∗ Some benefit from later-line
use
|
|
Orpathys
|
|
12
|
43%
|
49%
|
∗ Demand in in China for the treatment of patients
with NSCLC with MET exon 14 skipping
alterations
|
|
Other Oncology
|
|
107
|
(24%)
|
(19%)
|
∗ Decline in use of Iressa in China
|
BioPharmaceuticals
BioPharmaceuticals Total Revenue increased by 14% (16% at CER) in
Q1 2024 to $5,178m, representing 41% of overall Total Revenue (Q1
2023: 42%).
BioPharmaceuticals - CVRM
CVRM Total Revenue increased by 20% (23% at CER) to $3,060m in Q1
2024 and represented 24% of overall Total Revenue (Q1 2023:
24%).
Farxiga
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
1,892
|
|
475
|
711
|
553
|
152
|
|
Actual change
|
|
43%
|
|
61%
|
43%
|
41%
|
10%
|
|
CER change
|
|
45%
|
|
61%
|
50%
|
37%
|
18%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Farxiga volume
is growing faster than the overall SGLT2 market in most major
regions, fuelled by launches in heart failure and CKD, and also the
launch of an authorised generic in the US. SGLT2 class growth
underpinned by updated cardiorenal guidelines
|
|
US
|
|
∗ Growth driven by heart failure and
CKD
∗ Sales in the quarter benefitted from the
introduction of an authorised generic
|
|
Emerging Markets
|
|
∗ Solid growth despite entry of generic competition
in some markets
∗ Strong momentum in Latin
America
∗ Sales in the quarter benefited from the timing of
government tenders
|
|
Europe
|
|
∗ Continued strong
class growth and market share gains fuelled by HFpEF approval in
2023 and guidelines updates
|
|
Established RoW
|
|
∗ In Japan, a milestone payment of $45m was received
in the quarter from AstraZeneca's partner Ono Pharmaceutical Co.,
Ltd, which records in-market sales
|
Brilinta
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
323
|
|
163
|
88
|
67
|
5
|
|
Actual change
|
|
(3%)
|
|
(9%)
|
8%
|
(1%)
|
(12%)
|
|
CER change
|
|
(1%)
|
|
(9%)
|
21%
|
(3%)
|
(14%)
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ Stable volume but unfavourable gross-to-net
adjustments in the quarter
|
|
Emerging Markets
|
|
∗ Growth despite generics pressure in some
markets
|
|
Europe
|
|
∗ Declining volume
|
|
Established RoW
|
|
∗ Sales decline driven by generic entry in
Canada
|
Other CVRM medicines
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Crestor
|
|
297
|
(3%)
|
2%
|
∗ Continued sales growth in Emerging
Markets
|
|
Seloken
|
|
165
|
(8%)
|
(2%)
|
∗ Ongoing impact of China VBP
implementation
|
|
Lokelma
|
|
114
|
16%
|
19%
|
∗ Continued launches in new
markets
|
|
roxadustat
Andexxa
|
|
77
47
|
24%
6%
|
28%
6%
|
∗ Increased demand in both the dialysis and
non-dialysis-dependent populations. NRDL listing
renewed
∗ Growth driven by Europe
|
|
Wainua
|
|
5
|
n/m
|
n/m
|
∗ Approved for ATTRv-PN in the US in December
2023
|
|
Other CVRM
|
|
141
|
(33%)
|
(31%)
|
|
BioPharmaceuticals - R&I
Total Revenue of $1,886m from R&I medicines increased 15% (17%
at CER) and represented 15% of overall Total Revenue (Q1 2023:
15%). This reflected growth in Fasenra, Tezspire, Breztri, Saphnelo and Airsupra following its recent
launch.
Fasenra
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
358
|
|
210
|
22
|
93
|
33
|
|
Actual change
|
|
6%
|
|
5%
|
56%
|
6%
|
(6%)
|
|
CER change
|
|
6%
|
|
4%
|
61%
|
4%
|
-
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Continued asthma market share leadership in IL-5
class across major markets
|
|
US
|
|
∗ Maintained share of a growing
market
|
|
Emerging Markets
|
|
∗ Continued strong demand growth driven by launch
acceleration across key markets
|
|
Europe
|
|
∗ Expanded leadership in severe eosinophilic
asthma
|
|
Established RoW
|
|
∗ In Japan,
maintained class leadership in a broadly stable market
|
Breztri
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
219
|
|
105
|
70
|
30
|
14
|
|
Actual change
|
|
52%
|
|
30%
|
83%
|
97%
|
43%
|
|
CER change
|
|
54%
|
|
30%
|
91%
|
93%
|
53%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Fastest growing
medicine within the expanding FDC triple class, across
major markets
|
|
US
|
|
∗ Consistent share growth
within the FDC triple class in
new-to-brand and
the total market
|
|
Emerging Markets
|
|
∗ Maintained market share leadership in China with
strong triple FDC class penetration
∗ Further expansion with launches in additional
geographies
|
|
Europe
|
|
∗ Sustained growth across markets as new launches
continue to progress
|
|
Established RoW
|
|
∗ Increased market share within the COPD indication
in Japan and strong launch in Canada
|
Tezspire
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
120
|
|
77
|
2
|
27
|
14
|
|
Actual change
|
|
>2x
|
|
80%
|
n/m
|
>4x
|
>3x
|
|
CER change
|
|
>2x
|
|
80%
|
n/m
|
>3x
|
>3x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to
$216m in Q1 2024 (Q1 2023: $105m)
|
|
US
|
|
∗ Continued growth in total prescriptions, and
maintained new-to-brand market share with majority of patients new
to biologics
|
|
Europe
|
|
∗ Achieved new-to-brand leadership across multiple
markets, new launches continue to progress
|
|
Established RoW
|
|
∗ Japan maintained new-to-brand
leadership
|
Symbicort
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
769
|
|
299
|
253
|
142
|
75
|
|
Actual change
|
|
12%
|
|
28%
|
11%
|
(3%)
|
(5%)
|
|
CER change
|
|
14%
|
|
28%
|
18%
|
(6%)
|
(3%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Symbicort remained the global
market leader within a stable ICS/LABA class
|
|
US
|
|
∗ Encouraging
demand following list price reduction
|
|
Emerging Markets
|
|
∗ Strong
underlying demand for Symbicort in both China and
Ex-China Emerging Markets, strengthened position as market leader
in the region
|
|
Europe
|
|
∗ Continued price
and volume erosion from generics and a slowing overall
market
|
|
Established RoW
|
|
∗ Continued
generic erosion in Japan
|
Other R&I medicines
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Pulmicort
|
|
224
|
1%
|
5%
|
∗ >80% of
revenues from Emerging Markets
|
|
Saphnelo
|
|
91
|
94%
|
95%
|
∗ Demand
acceleration in the US, and additional growth driven by ongoing
launches in Europe and Established RoW
|
|
Airsupra
|
|
7
|
n/m
|
n/m
|
∗ Strong launch
momentum with increase class penetration and volume uptake. Revenue
in the quarter reflects introductory discounts as early access
continues to build
|
|
Other R&I
|
|
98
|
(30%)
|
(29%)
|
∗ Generic
competition
|
BioPharmaceuticals - V&I
Total Revenue from V&I medicines reduced by 35% (34% at CER) to
$232m (Q1 2023: $355m) and represented 2% of overall Total Revenue
(Q1 2023: 3%), principally due to a decline in sales of COVID-19
mAbs.
V&I medicines
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Beyfortus
|
|
46
|
n/m
|
n/m
|
∗ Product Sales recognises AstraZeneca's sales of
manufactured Beyfortus product to Sanofi
∗ Alliance Revenue recognises AstraZeneca's 50%
share of gross profits on sales of Beyfortus in major markets outside the US, and 25% of
brand revenues in rest of world markets
∗ AstraZeneca has no participation in US profits or
losses
|
|
Synagis
|
|
171
|
(13%)
|
(13%)
|
∗ Decline in Synagis more than offset by growth
in Beyfortus
|
|
COVID-19 mAbs
|
|
2
|
(99%)
|
(99%)
|
∗ Decline
in Evusheld sales
(Q1 2023: $127m)
|
|
FluMist
|
|
7
|
>2x
|
>2x
|
∗ Normal
seasonality
|
|
Other V&I
|
|
6
|
(79%)
|
(80%)
|
∗ Decline in Vaxzevria sales (Q1 2023: $28m)
|
Rare Disease
Total Revenue from Rare Disease medicines increased by 12% (16% at
CER) in Q1 2024 to $2,096m, representing 17% of overall Total
Revenue (Q1 2023: 17%).
Ultomiris
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
859
|
|
482
|
32
|
202
|
143
|
|
Actual change
|
|
32%
|
|
27%
|
>2x
|
27%
|
46%
|
|
CER change
|
|
34%
|
|
27%
|
>2x
|
24%
|
61%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Growth across neurology, geographic expansion,
patient demand and Soliris conversion
∗ Quarter-on-quarter variability in revenue growth
can be expected due to Ultomiris every eight-week dosing schedule and lower
average annual treatment cost compared to Soliris
|
|
US
|
|
∗ Growth in naïve patients in gMG and
conversion from Soliris across shared
indications
|
|
Emerging Markets
|
|
∗ Continued growth following launches in new
markets
|
|
Europe
|
|
∗ Strong demand generation following launches in new
markets, particularly in neurology indications, as well as
accelerated conversion from Soliris in key markets, partially offset by
price reductions to secure reimbursement for new
indications
|
|
Established RoW
|
|
∗ Continued conversion from Soliris and strong demand following new
launches
|
Soliris
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
739
|
|
411
|
125
|
142
|
61
|
|
Actual change
|
|
(11%)
|
|
(8%)
|
9%
|
(23%)
|
(30%)
|
|
CER change
|
|
(8%)
|
|
(8%)
|
37%
|
(24%)
|
(28%)
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ Decline driven by successful conversion
of Soliris patients to Ultomiris in PNH, aHUS and gMG, partially offset
by Soliris growth in NMOSD
|
|
Emerging Markets
|
|
∗ Growth driven by patient demand following launches
in new markets
|
|
Europe
|
|
∗ Decline driven by successful conversion
from Soliris to Ultomiris as well as biosimilar erosion in PNH and
aHUS
|
|
Established RoW
|
|
∗ Decline driven by successful conversion
from Soliris to Ultomiris
|
Strensiq
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2024 $m
|
|
313
|
|
246
|
21
|
24
|
22
|
|
Actual change
|
|
20%
|
|
20%
|
44%
|
15%
|
4%
|
|
CER change
|
|
21%
|
|
20%
|
67%
|
12%
|
14%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Growth driven by strong patient
demand
|
Other Rare Disease medicines
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Koselugo
|
|
132
|
68%
|
82%
|
∗ Driven by patient demand and expansion in new
markets. The quarter benefitted from tender market order timing in
Emerging Markets
|
|
Kanuma
|
|
53
|
32%
|
35%
|
∗ Continued global demand
|
Other medicines (outside the main therapy areas)
|
|
Q1 2024
|
Change
|
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Drivers
and commentary
|
|
Nexium
|
|
243
|
(2%)
|
7%
|
∗ Growth in Emerging Markets offset declines
elsewhere
|
|
Others
|
|
54
|
(25%)
|
(23%)
|
∗ Continued impact of generic
competition
|
Financial performance
Table 9:
Reported Profit and Loss
|
|
|
Q1 2024
|
Q1 2023
|
% Change
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
|
12,679
|
10,879
|
17
|
19
|
|
- Product Sales
|
|
12,177
|
10,566
|
15
|
18
|
|
- Alliance Revenue
|
|
457
|
286
|
59
|
59
|
|
- Collaboration Revenue
|
|
45
|
27
|
66
|
66
|
|
Cost of sales
|
|
(2,218)
|
(1,905)
|
16
|
18
|
|
Gross profit
|
|
10,461
|
8,974
|
17
|
20
|
|
Distribution expense
|
|
(135)
|
(134)
|
1
|
3
|
|
R&D expense
|
|
(2,783)
|
(2,611)
|
7
|
7
|
|
SG&A expense
|
|
(4,495)
|
(4,059)
|
11
|
12
|
|
Other operating income & expense
|
|
67
|
379
|
(83)
|
(83)
|
|
Operating profit
|
|
3,115
|
2,549
|
22
|
31
|
|
Net finance expense
|
|
(302)
|
(287)
|
5
|
1
|
|
Joint ventures and associates
|
|
(13)
|
-
|
n/m
|
n/m
|
|
Profit before tax
|
|
2,800
|
2,262
|
24
|
34
|
|
Taxation
|
|
(620)
|
(458)
|
35
|
46
|
|
Tax rate
|
|
22%
|
20%
|
|
|
|
Profit after tax
|
|
2,180
|
1,804
|
21
|
30
|
|
Earnings per share
|
|
$1.41
|
$1.16
|
21
|
30
|
Table 10:
Reconciliation of Reported Profit before tax to
EBITDA
|
|
|
Q1 2024
|
Q1 2023
|
% Change
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
|
2,800
|
2,262
|
24
|
34
|
|
Net finance expense
|
|
302
|
287
|
5
|
1
|
|
Joint ventures and associates
|
|
13
|
-
|
n/m
|
n/m
|
|
Depreciation, amortisation and impairment
|
|
1,255
|
1,502
|
(16)
|
(17)
|
|
EBITDA
|
|
4,370
|
4,051
|
8
|
13
|
Table 11:
Reconciliation of Reported to Core financial measures: Q1
2024[7]
|
Q1 2024
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
Core
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
|
10,461
|
20
|
10
|
-
|
10,491
|
15
|
18
|
|
Product Sales Gross Margin
|
|
82%
|
|
|
|
82%
|
-1pp
|
-1pp
|
|
Distribution expense
|
|
(135)
|
-
|
-
|
-
|
(135)
|
1
|
3
|
|
R&D expense
|
|
(2,783)
|
80
|
4
|
1
|
(2,698)
|
17
|
18
|
|
% of Total Revenue
|
|
22%
|
|
|
|
21%
|
-
|
-
|
|
SG&A expense
|
|
(4,495)
|
97
|
941
|
44
|
(3,413)
|
12
|
13
|
|
% of Total Revenue
|
|
35%
|
|
|
|
27%
|
+1pp
|
+1pp
|
|
Total operating expense
|
|
(7,413)
|
177
|
945
|
45
|
(6,246)
|
14
|
15
|
|
Other operating income & expense
|
|
67
|
(2)
|
-
|
-
|
65
|
(80)
|
(80)
|
|
Operating profit
|
|
3,115
|
195
|
955
|
45
|
4,310
|
9
|
15
|
|
Operating Margin
|
|
25%
|
|
|
|
34%
|
-2pp
|
-1pp
|
|
Net finance expense
|
|
(302)
|
-
|
-
|
57
|
(245)
|
2
|
(3)
|
|
Taxation
|
|
(620)
|
(45)
|
(183)
|
(19)
|
(867)
|
19
|
25
|
|
EPS
|
|
$1.41
|
$0.10
|
$0.50
|
$0.05
|
$2.06
|
7
|
13
|
Profit and Loss drivers
Gross profit
‒ The
calculation of Reported and Core Product Sales Gross Margin
excludes the impact of Alliance Revenue and Collaboration
Revenue
‒ The
change in Product Sales Gross Margin (Reported and Core) in Q1 2024
was impacted by:
‒ Positive
effects from product mix. The increased contribution from Rare
Disease and Oncology medicines had a positive impact on the Product
Sales Gross Margin
‒ Dilutive
effects from product mix. The rising contribution of Product Sales
with profit sharing arrangements (Lynparza,
Enhertu, Tezspire,
Koselugo) has a negative
impact on Product Sales Gross Margin because AstraZeneca records
Product Sales in certain markets and pays away a share of the gross
profits to its collaboration partners. The growth
in Beyfortus also has a dilutive impact on Product Sales
Gross Margin, as AstraZeneca is responsible for manufacturing, and
Sanofi is responsible for distribution. AstraZeneca records its
sales to Sanofi as Product Sales, which generate a lower Product
Sales Gross Margin than the Company average
‒ Dilutive
effects from geographic mix. In Emerging Markets, the Product Sales
Gross Margin tends to be below the Company
average
‒ Variations
in Product Sales Gross Margin performance between periods can
continue to be expected due to product seasonality, foreign
exchange fluctuations, and other effects
R&D expense
‒ The
change in R&D expense (Reported and Core) in the period was
impacted by:
‒ Recent
positive data read-outs for several high priority medicines that
have ungated late-stage trials
‒ Investment
in platforms, new technology and capabilities to enhance R&D
productivity
‒ The
change in Reported R&D expense was also impacted by intangible
asset impairments in the prior period
SG&A expense
‒ The
change in SG&A expense (Reported and Core) in the period was
driven primarily by market development activities for
launches
Other operating income and expense
‒ In
the prior year period, Other operating income and expense included
a $241m gain on the disposal of the US rights
to Pulmicort Flexhaler
Net finance expense
‒ Core
Net finance expense increased 2% (3% decrease at CER) with higher
rates on floating debt and bond issuances broadly offset by higher
interest received on cash and short-term
investments
Taxation
‒ The
effective Reported Tax rate for the three months to 31 March 2024
was 22% (Q1 2023: 20%) and the effective Core Tax rate was 21% (Q1
2023: 20%)
‒ The
cash tax paid for the three months to 31 March 2024 was $430m (Q1
2023: $225m), representing 15% of Reported Profit before tax (Q1
2023: 10%)
Table 12: Cash
Flow summary
|
|
|
Q1 2024
|
Q1 2023
|
Change
|
|
|
|
$m
|
$m
|
$m
|
|
Reported Operating profit
|
|
3,115
|
2,549
|
566
|
|
Depreciation, amortisation and impairment
|
|
1,255
|
1,502
|
(247)
|
|
Movement in working capital and short-term provisions
|
|
(455)
|
242
|
(697)
|
|
Gains on disposal of intangible assets
|
|
-
|
(249)
|
249
|
|
Fair value movements on contingent consideration arising
from
business combinations
|
|
16
|
-
|
16
|
|
Non-cash and other movements
|
|
(674)
|
(429)
|
(245)
|
|
Interest paid
|
|
(341)
|
(257)
|
(84)
|
|
Taxation paid
|
|
(430)
|
(225)
|
(205)
|
|
Net cash inflow from operating activities
|
|
2,486
|
3,133
|
(647)
|
|
Net cash inflow before financing activities
|
|
73
|
1,887
|
(1,814)
|
|
Net cash inflow/(outflow) from financing activities
|
|
2,028
|
(2,031)
|
4,059
|
The change in Net cash inflow before financing activities in the
quarter to 31 March 2024 is primarily driven by the movement in
Acquisitions of subsidiaries, net of cash acquired, of $537m, and
relates to the acquisition of Gracell Biotechnologies, Inc. for
$726m compared to the acquisition of Neogene Therapeutics, Inc. for
$189m in Q1 2023.
The change in Net cash inflow/(outflow) from financing activities
of $4,059m is primarily driven by the increase in Issue of loans
and borrowings of $1,150m, and by the decrease in Repayment of
loans and borrowings of $1,997m.
Capital expenditure
Capital expenditure amounted to $417m in the three months to 31
March 2024 (Q1 2023: $247m). Capital expenditure is expected to
increase substantially in 2024, driven by investment in several
major manufacturing projects and continued investment in technology
upgrades.
Table 13: Net
debt summary
|
|
At 31
Mar 2024
|
At 31
Dec 2023
|
At 31
Mar 2023
|
|
|
$m
|
$m
|
$m
|
|
Cash and cash equivalents
|
7,841
|
5,840
|
6,232
|
|
Other investments
|
180
|
122
|
230
|
|
Cash and investments
|
8,021
|
5,962
|
6,462
|
|
Overdrafts and short-term borrowings
|
(477)
|
(515)
|
(593)
|
|
Commercial paper
|
(980)
|
-
|
(74)
|
|
Lease liabilities
|
(1,242)
|
(1,128)
|
(962)
|
|
Current instalments of loans
|
(4,593)
|
(4,614)
|
(2,958)
|
|
Non-current instalments of loans
|
(27,259)
|
(22,365)
|
(26,916)
|
|
Interest-bearing loans and borrowings (Gross debt)
|
(34,551)
|
(28,622)
|
(31,503)
|
|
Net derivatives
|
81
|
150
|
(21)
|
|
Net debt
|
(26,449)
|
(22,510)
|
(25,062)
|
Net debt increased by $3,939m in the three months to 31 March 2024
to $26,449m. Details of the committed undrawn bank facilities are
disclosed within the going concern section of Note 1. Details of
the Company's solicited credit ratings and further details on Net
debt are disclosed in Note 3.
Capital allocation
The Board's aim is to continue to strike a balance between the
interests of the business, financial creditors and the Company's
shareholders. The Company's capital allocation priorities include:
investing in the business and pipeline; maintaining a strong,
investment-grade credit rating; potential value-enhancing business
development opportunities; and supporting the progressive dividend
policy.
In approving the declaration of dividends, the Board considers both
the liquidity of the company and the level of reserves legally
available for distribution. Dividends are paid to shareholders from
AstraZeneca PLC, a Group holding company with no direct operations.
The ability of AstraZeneca PLC to make shareholder distributions is
dependent on the creation of profits for distribution and the
receipt of funds from subsidiary companies. The consolidated Group
reserves set out in the Condensed consolidated statement of
financial position do not reflect the profit available for
distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities of
subsidiaries
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of
0.7% Notes due 2024, 1.2% Notes due 2026, 4.8% Notes due 2027,
4.875% Notes due 2028, 1.75% Notes due 2028, 4.85% Notes due 2029,
4.9% Notes due 2030, 4.9% Notes due 2031, 2.25% Notes due 2031,
4.875% Notes due 2033 and 5% Notes due 2034 (the "AstraZeneca
Finance Notes"). Each series of AstraZeneca Finance Notes has been
fully and unconditionally guaranteed by AstraZeneca PLC.
AstraZeneca Finance is 100% owned by AstraZeneca PLC and each of
the guarantees issued by AstraZeneca PLC is full and unconditional
and joint and several.
The AstraZeneca Finance Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance Notes is the senior unsecured obligation of AstraZeneca PLC
and ranks equally with all of AstraZeneca PLC's existing and future
senior unsecured and unsubordinated indebtedness. Each guarantee by
AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the
assets securing such indebtedness. The AstraZeneca Finance Notes
are structurally subordinated to indebtedness and other liabilities
of the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance Notes.
AstraZeneca PLC manages substantially all of its operations through
divisions, branches and/or investments in subsidiaries and
affiliates. Accordingly, the ability of AstraZeneca PLC to service
its debt and guarantee obligations is also dependent upon the
earnings of its subsidiaries, affiliates, branches and divisions,
whether by dividends, distributions, loans or
otherwise.
Please refer to the Consolidated financial statements of
AstraZeneca PLC in our Annual Report on Form 20-F and reports on
Form 6-K with our quarterly financial results as filed or furnished
with the SEC for further financial information regarding
AstraZeneca PLC and its consolidated subsidiaries. For further
details, terms and conditions of the AstraZeneca Finance Notes
please refer to AstraZeneca PLC's reports on Form 6-K furnished to
the SEC on 22 February 2024, 3 March 2023 and 28 May
2021.
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the
Securities Act of 1933, as amended (the "Securities Act"), we
present below the summary financial information for AstraZeneca
PLC, as Guarantor, excluding its consolidated subsidiaries, and
AstraZeneca Finance, as the issuer, excluding its consolidated
subsidiaries. The following summary financial information of
AstraZeneca PLC and AstraZeneca Finance is presented on a combined
basis and transactions between the combining entities have been
eliminated. Financial information for non-guarantor entities has
been excluded. Intercompany balances and transactions between the
obligor group and the non-obligor subsidiaries are presented on
separate lines.
Table 14:
Obligor group summarised Statement of comprehensive
income
|
|
|
Q1 2024
|
Q1 2023
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
-
|
-
|
|
Gross profit
|
|
-
|
-
|
|
Operating loss
|
|
-
|
-
|
|
Loss for the period
|
|
(234)
|
(237)
|
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
588
|
7,502
|
Table 15:
Obligor group summarised Statement of financial
position
|
|
|
At 31 Mar 2024
|
At 31 Mar 2023
|
|
|
|
$m
|
$m
|
|
Current assets
|
|
12
|
10
|
|
Non-current assets
|
|
-
|
-
|
|
Current liabilities
|
|
(5,778)
|
(2,952)
|
|
Non-current liabilities
|
|
(27,161)
|
(26,747)
|
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
21,242
|
14,067
|
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
-
|
(296)
|
Foreign exchange
The Company's transactional currency exposures on working capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign exchange contracts against
the individual companies' reporting currency. Foreign exchange
gains and losses on forward contracts transacted for transactional
hedging are taken to profit or to Other comprehensive income if the
contract is in a designated cashflow hedge. In addition, the
Company's external dividend payments, paid principally in pound
sterling and Swedish krona, are fully hedged from announcement to
payment date.
Table 16:
Currency sensitivities
The Company provides the following information on
currency-sensitivity:
|
|
|
|
Average
rates vs. USD
|
|
Annual impact ($m) of 5% strengthening (FY 2024 average rate vs. FY
2023 average) [8]
|
||||||||
|
Currency
|
Primary Relevance
|
|
FY 2023[9]
|
YTD 2024[10]
|
Change
(%)
|
Mar 2024[11]
|
Change
(%)
|
|
Total Revenue
|
Core Operating Profit
|
|||
|
EUR
|
Total Revenue
|
|
0.92
|
0.92
|
0
|
0.92
|
0
|
|
397
|
179
|
|||
|
CNY
|
Total Revenue
|
|
7.09
|
7.20
|
(2)
|
7.22
|
(2)
|
|
322
|
182
|
|||
|
JPY
|
Total Revenue
|
|
140.60
|
148.49
|
(5)
|
149.87
|
(6)
|
|
177
|
119
|
|||
|
Other[12]
|
|
|
|
|
|
|
|
|
453
|
227
|
|||
|
GBP
|
Operating expense
|
|
0.80
|
0.79
|
2
|
0.79
|
2
|
|
60
|
(126)
|
|||
|
SEK
|
Operating expense
|
|
10.61
|
10.39
|
2
|
10.41
|
2
|
|
9
|
(63)
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sustainability
AstraZeneca published its tenth
annual Sustainability
Report,
including a data annex for performance measures and targets, along
with the 2023 Taskforce on Climate-related Financial Disclosures
Statement.
Access to healthcare
‒ Chair
Michel Demaré participated in a panel discussion with global
health leaders at the 54th Annual
Meeting of the World Economic Forum (WEF) in Davos on utilising
learnings from the COVID-19 pandemic to prepare for future health
challenges and the importance of investing in strong, resilient
health systems.
‒ Engagements
linked to the Partnership for Health
System Sustainability and Resilience (PHSSR),
continued in Germany, Belgium, Switzerland and Japan, highlighting
the need for measurable policy targets for non-communicable disease
management. In India, a PHSSR report was published assessing the
sustainability and resilience of the Indian health system, while in
the Netherlands, an academic publication was launched with policy
recommendations to improve health system
resilience.
‒ Healthy
Heart Africa (HHA), AstraZeneca's flagship
health equity programme, reached its goal of identifying more than
10 million people with elevated blood pressure by 2025 nearly
two years ahead of target. At the end of February 2024, more
than 11,480 healthcare
workers have been trained and more than 52 million blood
pressure screenings conducted cumulatively since the programme
launched in 2014, maintaining an average of more than one million
screenings per month since 2023. HHA also launched a pilot
programme in Ghana in March 2024 as a first step to broadening its
scope to include chronic kidney disease
screening.
‒ Since
2021, the Young Health Programme (YHP) has directly reached
more than 10 million youth, influenced 16 policies and has employee
volunteer programmes in 36 countries, exceeding its core targets
for 2021-2025 nearly two years early. YHP received the Driving
Health Equity Award in the 2024 Reuters Pharma Awards Europe for
the programme's work empowering young people to catalyse a
healthier future.
Environmental protection
‒ The
Company signed a clean heat agreement in March 2024 to decarbonise
our medicines manufacturing in China. Through the agreement,
biomethane and biomethane-based steam will be supplied to our Wuxi
manufacturing site and we will reduce our Scope 1 and 2 greenhouse
gas (GHG) emissions by up to 80% in China, supporting the broader
decarbonisation of the healthcare system.
‒ The
Company announced at WEF that it will be one of
the inaugural Early Adopter organisations that intend to start
making disclosures aligned with the Taskforce on
Nature-related Financial
Disclosures (TNFD) Recommendations in corporate reporting
by the fiscal year 2024.
‒ AstraZeneca
was one of the five healthcare companies, convened through the
Sustainable Markets Initiative Health Systems Task Force, that
launched an industry-first multi-party agreement to access
renewable power in China in January 2024. This is the first
time companies from across the global healthcare sector have come
together to decarbonise their operations in China, and the
agreement will result in potential annual emissions savings of
approximately 120,000 tonnes of carbon dioxide equivalent
(CO2e).
‒ AstraZeneca
received the Sustainability Award in the 2024 Reuters Pharma Awards
Europe for accelerating the electronic product information industry
transition in Europe.
Ethics and transparency
‒ The
Company achieved seventh place overall, and third in the Health
Care sector, in the FTSE Women Leaders Review 2023, as one of the
top performers in both the FTSE 100 and FTSE 350 for representation
of women across the organisation.
‒ The
Company's latest Modern Slavery Act Statement was published
detailing activities undertaken to mitigate the risks of modern
slavery both within the Company's operations and supply chain, in
line with the Code of Ethics and our commitment to operating with
integrity and in compliance with relevant
legislation.
‒ In
Poland, AstraZeneca was named an 'Ethics Leader' by Bonnier Press
for the third year. This award recognises five companies for their
commitment to upholding high ethical standards, treating business
partners with respect, applying the principles of fair competition,
and building trust and good relationships between employees and
stakeholder groups.
Research and development
This section covers R&D events and milestones that have
occurred since the prior results announcement on 8 February
2024, up to and including events on 24 April 2024.
A comprehensive view of AstraZeneca's pipeline of medicines in
human trials can be found in the latest Clinical Trials Appendix,
available on www.astrazeneca.com/investor-relations.
The Clinical Trials Appendix includes tables with details of the
ongoing clinical trials for AstraZeneca medicines and new molecular
entities in the pipeline.
Oncology
AstraZeneca presented new data across its diverse portfolio of
cancer medicines at four major medical congresses since the prior
results announcement: the Society of Gynecologic Oncology Annual
Meeting on Women's Cancer (SGO) in March 2024, the European Lung
Cancer Congress (ELCC) in March 2024, American Association for
Cancer Research Annual Meeting (AACR) in April 2024 and the 2024
Cholangiocarcinoma Foundation Conference (CFC) in April
2024.
Tagrisso
|
Event
|
|
|
Commentary
|
|
Phase III trial read out
|
LAURA
|
|
Met primary endpoint, demonstrating that Tagrisso resulted in a statistically significant and
highly clinically meaningful improvement in PFS for patients with
unresectable, Stage III EGFRm NSCLC after chemoradiotherapy
compared to placebo after chemoradiotherapy. (February
2024)
|
|
Approval
|
US
|
|
Tagrisso with the addition
of chemotherapy for the treatment of adult patients with locally
advanced or metastatic EGFRm NSCLC. (FLAURA2, February
2024)
|
|
Presentation: ELCC
|
FLAURA2
|
|
OS interim analysis of the Phase III FLAURA2 trial, presented at
ELCC, showed at 41% data maturity, a favourable trend with
the Tagrisso plus chemotherapy arm (HR 0.75)
vs Tagrisso monotherapy. The OS data were not
statistically significant at this interim analysis and will
continue to be assessed as a key secondary endpoint at final
analysis. (March 2024)
|
Imfinzi and Imjudo
|
Event
|
|
|
Commentary
|
|
Phase III trial read out
|
ADRIATIC
|
|
Met primary endpoint, demonstrating that Imfinzi resulted in a statistically significant and
clinically meaningful improvement in the dual primary endpoints of
OS and PFS in patients with LS-SCLC who had not progressed
following cCRT compared to placebo after cCRT. (April
2024).
|
|
Presentation: CFC
|
TOPAZ-1
|
|
Updated exploratory results of the Phase III TOPAZ-1 trial,
presented at CFC, showed Imfinzi in combination with standard-of-care
chemotherapy demonstrated a clinically meaningful long-term OS
benefit at three years for patients with advanced BTC. (April
2024)
|
Lynparza
|
Event
|
|
|
Commentary
|
|
Presentation: SGO
|
DUO-E (Lynparza and Imfinzi)
|
|
Post-hoc exploratory subgroup analysis of the Phase III DUO-E
trial, presented at SGO, assessed patients by mismatch repair
status and demonstrated that median duration of response in
proficient mismatch repair patients in the Lynparza and Imfinzi arm was more than double versus the control
arm (18.7 versus 7.6 months) in patients with advanced or recurrent
endometrial cancer. (March 2024)
|
Enhertu
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For the treatment of adult patients with unresectable or metastatic
HER2-positive (IHC 3+) solid tumours who have received prior
systemic treatment and have no satisfactory alternative treatment
options (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02, April
2024)
|
Truqap
|
Event
|
|
|
Commentary
|
|
Approval
|
Japan
|
|
In combination with Faslodex for the treatment of adult patients with
unresectable or recurrent PIK3CA, AKT1, or PTEN-altered HR-positive, HER2-negative breast cancer
following progression after treatment with endocrine therapy.
(CAPItello-291, March 2024)
|
BioPharmaceuticals - R&I
Fasenra
|
Event
|
|
|
Commentary
|
|
Label expansion
|
US
|
|
Fasenra's approval in severe
eosinophilic asthma has been expanded to include patients 6 years
and older, from the previous 12 years and older (TATE, April
2024)
|
|
Publication (Respiratory
Medicine)
|
MIRACLE
|
|
Results from the MIRACLE Phase III trial showed treatment
with Fasenra resulted in a reduction of 74% in annual
exacerbation rate in patients in Asia with severe eosinophilic
asthma (April 2024)
|
Rare Disease
AstraZeneca presented new clinical and real-world data from its
leading rare neurology portfolio at the American Academy of
Neurology (AAN) Annual Meeting in Denver, CO, 13 to 18 April 2024.
The Company presented 14 abstracts, including five oral
presentations, across both gMG and NMOSD.
Ultomiris
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For the treatment of adult patients with anti-aquaporin-4
antibody-positive (Ab+) NMOSD. (CHAMPION-NMOSD, March
2024)
|
Voydeya
|
Event
|
|
|
Commentary
|
|
Approval
|
US
|
|
For the treatment of extravascular haemolysis in adults with
paroxysmal nocturnal haemoglobinuria, as add-on therapy
to Ultomiris or Soliris. (ALPHA, April 2024)
|
|
Approval
|
EU
|
|
For the treatment of adult patients with paroxysmal nocturnal
haemoglobinuria who have residual haemolytic anaemia, as an add-on
therapy to Ultomiris or Soliris. (ALPHA, February 2024).
|
Interim financial statements
Table 17:
Condensed consolidated statement of comprehensive income: Q1
2024
|
For the quarter ended 31 March
|
|
2024
|
2023
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
12,679
|
10,879
|
|
Product Sales
|
|
12,177
|
10,566
|
|
Alliance Revenue
|
|
457
|
286
|
|
Collaboration Revenue
|
|
45
|
27
|
|
Cost of sales
|
|
(2,218)
|
(1,905)
|
|
Gross profit
|
|
10,461
|
8,974
|
|
Distribution expense
|
|
(135)
|
(134)
|
|
Research and development expense
|
|
(2,783)
|
(2,611)
|
|
Selling, general and administrative expense
|
|
(4,495)
|
(4,059)
|
|
Other operating income and expense
|
|
67
|
379
|
|
Operating profit
|
|
3,115
|
2,549
|
|
Finance income
|
|
111
|
78
|
|
Finance expense
|
|
(413)
|
(365)
|
|
Share of after tax losses in associates and joint
ventures
|
|
(13)
|
-
|
|
Profit before tax
|
|
2,800
|
2,262
|
|
Taxation
|
|
(620)
|
(458)
|
|
Profit for the period
|
|
2,180
|
1,804
|
|
Other comprehensive income:
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
144
|
(10)
|
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
|
35
|
46
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
-
|
2
|
|
Tax on items that will not be reclassified to profit or
loss
|
|
(39)
|
24
|
|
|
|
140
|
62
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
Foreign exchange arising on consolidation
|
|
(515)
|
314
|
|
Foreign exchange arising on designated liabilities in net
investment hedges
|
|
(98)
|
(7)
|
|
Fair value movements on cash flow hedges
|
|
(86)
|
56
|
|
Fair value movements on cash flow hedges transferred to profit and
loss
|
|
70
|
(75)
|
|
Fair value movements on derivatives designated in net investment
hedges
|
|
22
|
16
|
|
Costs of hedging
|
|
15
|
-
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
35
|
12
|
|
|
|
(557)
|
316
|
|
Other comprehensive (expense)/income, net of tax
|
|
(417)
|
378
|
|
Total comprehensive income for the period
|
|
1,763
|
2,182
|
|
Profit attributable to:
|
|
|
|
|
Owners of the Parent
|
|
2,179
|
1,803
|
|
Non-controlling interests
|
|
1
|
1
|
|
|
|
2,180
|
1,804
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners of the Parent
|
|
1,762
|
2,181
|
|
Non-controlling interests
|
|
1
|
1
|
|
|
|
1,763
|
2,182
|
|
Basic earnings per $0.25 Ordinary Share
|
|
$1.41
|
$1.16
|
|
Diluted earnings per $0.25 Ordinary Share
|
|
$1.40
|
$1.16
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
|
1,549
|
1,549
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
|
1,560
|
1,560
|
Table 18:
Condensed consolidated statement of financial
position
|
|
|
At 31 Mar
2024
|
At 31 Dec
2023
|
At 31 Mar
2023
|
|
|
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
Property, plant and equipment
|
|
9,411
|
9,402
|
8,644
|
|
Right-of-use assets
|
|
1,205
|
1,100
|
955
|
|
Goodwill
|
|
19,978
|
20,048
|
20,001
|
|
Intangible assets
|
|
38,834
|
38,089
|
39,291
|
|
Investments in associates and joint ventures
|
|
130
|
147
|
77
|
|
Other investments
|
|
1,565
|
1,530
|
1,157
|
|
Derivative financial instruments
|
|
213
|
228
|
116
|
|
Other receivables
|
|
745
|
803
|
682
|
|
Deferred tax assets
|
|
4,618
|
4,718
|
3,498
|
|
|
|
76,699
|
76,065
|
74,421
|
|
Current assets
|
|
|
|
|
|
Inventories
|
|
5,337
|
5,424
|
4,967
|
|
Trade and other receivables
|
|
11,072
|
12,126
|
10,289
|
|
Other investments
|
|
180
|
122
|
230
|
|
Derivative financial instruments
|
|
11
|
116
|
40
|
|
Income tax receivable
|
|
1,153
|
1,426
|
508
|
|
Cash and cash equivalents
|
|
7,841
|
5,840
|
6,232
|
|
|
|
25,594
|
25,054
|
22,266
|
|
Total assets
|
|
102,293
|
101,119
|
96,687
|
|
Liabilities
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(6,050)
|
(5,129)
|
(3,625)
|
|
Lease liabilities
|
|
(281)
|
(271)
|
(232)
|
|
Trade and other payables
|
|
(19,699)
|
(22,374)
|
(19,210)
|
|
Derivative financial instruments
|
|
(92)
|
(156)
|
(44)
|
|
Provisions
|
|
(1,148)
|
(1,028)
|
(546)
|
|
Income tax payable
|
|
(1,631)
|
(1,584)
|
(1,203)
|
|
|
|
(28,901)
|
(30,542)
|
(24,860)
|
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(27,259)
|
(22,365)
|
(26,916)
|
|
Lease liabilities
|
|
(961)
|
(857)
|
(730)
|
|
Derivative financial instruments
|
|
(51)
|
(38)
|
(133)
|
|
Deferred tax liabilities
|
|
(2,621)
|
(2,844)
|
(2,795)
|
|
Retirement benefit obligations
|
|
(1,280)
|
(1,520)
|
(1,128)
|
|
Provisions
|
|
(1,123)
|
(1,127)
|
(914)
|
|
Other payables
|
|
(2,596)
|
(2,660)
|
(3,400)
|
|
|
|
(35,891)
|
(31,411)
|
(36,016)
|
|
Total liabilities
|
|
(64,792)
|
(61,953)
|
(60,876)
|
|
Net assets
|
|
37,501
|
39,166
|
35,811
|
|
Equity
|
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
|
Share capital
|
|
388
|
388
|
387
|
|
Share premium account
|
|
35,194
|
35,188
|
35,159
|
|
Other reserves
|
|
2,075
|
2,065
|
2,068
|
|
Retained earnings
|
|
(212)
|
1,502
|
(1,825)
|
|
|
|
37,445
|
39,143
|
35,789
|
|
Non-controlling interests
|
|
56
|
23
|
22
|
|
Total equity
|
|
37,501
|
39,166
|
35,811
|
Table 19: Condensed consolidated statement of changes in
equity
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2023
|
|
387
|
35,155
|
2,069
|
(574)
|
37,037
|
21
|
37,058
|
|
Profit for the period
|
|
-
|
-
|
-
|
1,803
|
1,803
|
1
|
1,804
|
|
Other comprehensive income
|
|
-
|
-
|
-
|
378
|
378
|
-
|
378
|
|
Transfer to other reserves
|
|
-
|
-
|
(1)
|
1
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,047)
|
(3,047)
|
-
|
(3,047)
|
|
Issue of Ordinary Shares
|
|
-
|
4
|
-
|
-
|
4
|
-
|
4
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
132
|
132
|
-
|
132
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(518)
|
(518)
|
-
|
(518)
|
|
Net movement
|
|
-
|
4
|
(1)
|
(1,251)
|
(1,248)
|
1
|
(1,247)
|
|
At 31 Mar 2023
|
|
387
|
35,159
|
2,068
|
(1,825)
|
35,789
|
22
|
35,811
|
|
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2024
|
|
388
|
35,188
|
2,065
|
1,502
|
39,143
|
23
|
39,166
|
|
Profit for the period
|
|
-
|
-
|
-
|
2,179
|
2,179
|
1
|
2,180
|
|
Other comprehensive expense
|
|
-
|
-
|
-
|
(417)
|
(417)
|
-
|
(417)
|
|
Transfer to other reserves
|
|
-
|
-
|
10
|
(10)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,052)
|
(3,052)
|
-
|
(3,052)
|
|
Issue of Ordinary Shares
|
|
-
|
6
|
-
|
-
|
6
|
-
|
6
|
|
Changes in non-controlling interests
|
|
-
|
-
|
-
|
-
|
-
|
32
|
32
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
159
|
159
|
-
|
159
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(573)
|
(573)
|
-
|
(573)
|
|
Net movement
|
|
-
|
6
|
10
|
(1,714)
|
(1,698)
|
33
|
(1,665)
|
|
At 31 Mar 2024
|
|
388
|
35,194
|
2,075
|
(212)
|
37,445
|
56
|
37,501
|
Table 20:
Condensed consolidated statement of cash flows
|
For the quarter ended 31 March
|
|
2024
|
2023
|
|
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
|
|
Profit before tax
|
|
2,800
|
2,262
|
|
Finance income and expense
|
|
302
|
287
|
|
Share of after tax losses of associates and joint
ventures
|
|
13
|
-
|
|
Depreciation, amortisation and impairment
|
|
1,255
|
1,502
|
|
Movement in working capital and short-term provisions
|
|
(455)
|
242
|
|
Gains on disposal of intangible assets
|
|
-
|
(249)
|
|
Fair value movements on contingent consideration arising from
business combinations
|
|
16
|
-
|
|
Non-cash
and other movements
|
|
(674)
|
(429)
|
|
Cash generated from operations
|
|
3,257
|
3,615
|
|
Interest paid
|
|
(341)
|
(257)
|
|
Tax paid
|
|
(430)
|
(225)
|
|
Net cash inflow from operating activities
|
|
2,486
|
3,133
|
|
Cash flows from investing activities
|
|
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
|
(726)
|
(189)
|
|
Payments upon vesting of employee share awards attributable to
business combinations
|
|
-
|
(23)
|
|
Payment of contingent consideration from business
combinations
|
|
(222)
|
(214)
|
|
Purchase of property, plant and equipment
|
|
(417)
|
(247)
|
|
Disposal of property, plant and equipment
|
|
53
|
125
|
|
Purchase of intangible assets
|
|
(1,188)
|
(1,223)
|
|
Disposal of intangible assets
|
|
75
|
264
|
|
Movement in profit-participation liability
|
|
-
|
175
|
|
Purchase of non-current asset investments
|
|
(41)
|
-
|
|
Disposal of non-current asset investments
|
|
9
|
10
|
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
|
(57)
|
9
|
|
Disposal of investments in associates and joint
ventures
|
|
8
|
-
|
|
Interest received
|
|
93
|
67
|
|
Net cash outflow from investing activities
|
|
(2,413)
|
(1,246)
|
|
Net cash inflow before financing activities
|
|
73
|
1,887
|
|
Cash flows from financing activities
|
|
|
|
|
Proceeds from issue of share capital
|
|
6
|
4
|
|
Issue of loans and borrowings
|
|
4,976
|
3,826
|
|
Repayment of loans and borrowings
|
|
(7)
|
(2,004)
|
|
Dividends paid
|
|
(3,033)
|
(3,047)
|
|
Hedge contracts relating to dividend payments
|
|
(8)
|
27
|
|
Repayment of obligations under leases
|
|
(74)
|
(67)
|
|
Movement in short-term borrowings
|
|
1,001
|
97
|
|
Payment of Acerta Pharma share purchase liability
|
|
(833)
|
(867)
|
|
Net cash inflow/(outflow) from financing activities
|
|
2,028
|
(2,031)
|
|
Net increase/(decrease) in Cash and cash equivalents in the
period
|
|
2,101
|
(144)
|
|
Cash and cash equivalents at the beginning of the
period
|
|
5,637
|
5,983
|
|
Exchange rate effects
|
|
(46)
|
(11)
|
|
Cash and cash equivalents at the end of the period
|
|
7,692
|
5,828
|
|
Cash and cash equivalents consist of:
|
|
|
|
|
Cash and cash equivalents
|
|
7,841
|
6,232
|
|
Overdrafts
|
|
(149)
|
(404)
|
|
|
|
7,692
|
5,828
|
Notes to the Interim financial statements
Note 1: Basis of preparation and accounting policies
These unaudited condensed consolidated Interim financial statements
for the three months ended 31 March 2024 have been prepared in
accordance with International Accounting Standard 34, 'Interim
Financial Reporting' (IAS 34), as issued by the International
Accounting Standards Board (IASB), IAS 34 as adopted by the
European Union, UK-adopted IAS 34 and the Disclosure Guidance and
Transparency Rules sourcebook of the United Kingdom's Financial
Conduct Authority and with the requirements of the Companies Act
2006 as applicable to companies reporting under those
standards.
The unaudited Interim financial statements for the three months
ended 31 March 2024 were approved by the Board of Directors for
publication on 25 April 2024.
This results announcement does not constitute statutory accounts of
the Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The annual financial statements of the Group
for the year ended 31 December 2023 were prepared in accordance
with UK-adopted international accounting standards and with the
requirements of the Companies Act 2006. The annual financial
statements also comply fully with IFRS Accounting Standards as
issued by the IASB and International Accounting Standards as
adopted by the European Union. Except for the estimation of the
interim income tax charge, the Interim financial statements have
been prepared applying the accounting policies that were applied in
the preparation of the Group's published consolidated financial
statements for the year ended 31 December 2023.
The comparative figures for the financial year ended 31 December
2023 are not the Group's statutory accounts for that financial
year. Those accounts have been reported on by the Group's auditors
and will be delivered to the Registrar of Companies; their report
was (i) unqualified, (ii) did not include a reference to any
matters to which the auditors drew attention by way of emphasis
without qualifying their report, and (iii) did not contain a
statement under section 498(2) or (3) of the Companies Act
2006.
Going concern
The Group has considerable financial resources available. As at 31
March 2024, the Group has $14.7bn in financial resources (cash and
cash equivalent balances of $7.8bn and undrawn committed bank
facilities of $6.9bn, with $6.3bn of borrowings due within one
year). These facilities contain no financial covenants and were
undrawn at 31 March 2024. $2bn of the facilities are available
until February 2025 and the other $4.9bn are available until April
2029.
The Group's revenues are largely derived from sales of medicines
covered by patents, which provide a relatively high level of
resilience and predictability to cash inflows, although government
price interventions in response to budgetary constraints are
expected to continue to adversely affect revenues in some of our
significant markets. The Group, however, anticipates new revenue
streams from both recently launched medicines and those in
development, and the Group has a wide diversity of customers and
suppliers across different geographic areas.
Consequently, the Directors believe that, overall, the Group is
well placed to manage its business risks successfully. Accordingly,
they continue to adopt the going concern basis in preparing the
Interim financial statements.
Legal proceedings
The information contained in Note 6 updates the disclosures
concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form
20-F Information 2023.
Note 2: Intangible assets
In accordance with IAS 36 'Impairment of Assets', reviews for
triggers of impairment or impairment reversals at an individual
asset or cash generating unit level were conducted, and impairment
tests carried out where triggers were identified. This review
resulted in $nil impairment charge during the three months ended 31
March 2024 (31 March 2023: $271m net charge). In Q1 2023, net
impairment charges included the $244m impairment of the ALXN1840
intangible asset, following the decision to discontinue this
development programme in Wilson's disease.
The acquisition of Icosavax, Inc. completed on 19 February 2024.
The transaction is recorded as an asset acquisition based on the
concentration test permitted under IFRS 3 'Business Combinations',
with consideration of $841m principally relating to $639m of
intangible assets, $141m of cash and cash equivalents and $51m of
marketable securities. Contingent consideration of up to $300m
could be paid on achievement of regulatory and sales milestones;
these potential liabilities would be recorded when relevant
milestones are triggered or performance conditions
satisfied.
Note 3: Net debt
The table below provides an analysis of Net debt and a
reconciliation of Net Cash flow to the movement in Net debt. The
Group monitors Net debt as part of its capital management policy as
described in Note 28 of the Annual Report and Form
20-F Information 2023. Net
debt is a non-GAAP financial measure.
Table 21: Net
debt
|
|
|
At 1 Jan 2024
|
Cash flow
|
Acquisitions
|
Non-cash& other
|
Exchange movements
|
At 31 Mar 2024
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
|
(22,365)
|
(4,976)
|
(3)
|
(2)
|
87
|
(27,259)
|
|
Non-current instalments of leases
|
|
(857)
|
-
|
(2)
|
(114)
|
12
|
(961)
|
|
Total long-term debt
|
|
(23,222)
|
(4,976)
|
(5)
|
(116)
|
99
|
(28,220)
|
|
Current instalments of loans
|
|
(4,614)
|
7
|
(9)
|
(1)
|
24
|
(4,593)
|
|
Current instalments of leases
|
|
(271)
|
86
|
(2)
|
(100)
|
6
|
(281)
|
|
Commercial paper
|
|
-
|
(980)
|
-
|
-
|
-
|
(980)
|
|
Bank collateral received
|
|
(215)
|
60
|
-
|
-
|
-
|
(155)
|
|
Other short-term borrowings excluding overdrafts
|
|
(97)
|
(81)
|
-
|
-
|
5
|
(173)
|
|
Overdrafts
|
|
(203)
|
54
|
-
|
-
|
-
|
(149)
|
|
Total current debt
|
|
(5,400)
|
(854)
|
(11)
|
(101)
|
35
|
(6,331)
|
|
Gross borrowings
|
|
(28,622)
|
(5,830)
|
(16)
|
(217)
|
134
|
(34,551)
|
|
Net derivative financial instruments
|
|
150
|
8
|
-
|
(77)
|
-
|
81
|
|
Net borrowings
|
|
(28,472)
|
(5,822)
|
(16)
|
(294)
|
134
|
(34,470)
|
|
Cash and cash equivalents
|
|
5,840
|
1,837
|
209
|
1
|
(46)
|
7,841
|
|
Other investments - current
|
|
122
|
57
|
3
|
-
|
(2)
|
180
|
|
Cash and investments
|
|
5,962
|
1,894
|
212
|
1
|
(48)
|
8,021
|
|
Net debt
|
|
(22,510)
|
(3,928)
|
196
|
(293)
|
86
|
(26,449)
|
Net debt increased by $3,939m in the three months to 31 March 2024
to $26,449m. Details of the committed undrawn bank facilities are
disclosed within the going concern section of Note 1. Non-cash
movements in the period include fair value adjustments under IFRS 9
'Financial Instruments'.
In February 2024, AstraZeneca issued the following:
- $1,250m
of fixed-rate notes with a coupon of 4.8% maturing in February
2027
- $1,250m
of fixed-rate notes with a coupon of 4.85% maturing in February
2029
- $1,000m
of fixed-rate notes with a coupon of 4.9% maturing in February
2031
- $1,500m
of fixed-rate notes with a coupon of 5% maturing in February
2034
-
The Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group at 31 March 2024
was $155m (31 December 2023: $215m) and the carrying value of such
cash collateral posted by the Group at 31 March 2024 was $136m (31
December 2023: $102m).
The equivalent GAAP measure to Net debt is 'liabilities arising
from financing activities', which excludes the amounts for cash and
overdrafts, other investments and non-financing derivatives shown
above and includes the Acerta Pharma share purchase liability of
$nil (31 December 2023: $833m).
During the quarter ended 31 March 2024, there have been no changes
to the Company's solicited long term credit ratings. Moody's credit
ratings were long term: A2; short term: P-1. Standard and Poor's
credit ratings were long term: A; short term: A-1.
Note 4: Financial Instruments
As detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
The Group has certain equity investments that are categorised as
Level 3 in the fair value hierarchy that are held at $309m at (31
December 2023: $313m) and for which a fair value loss of $1m has
been recognised in the three months ended 31 March 2024 (31 March
2023: fair value gain of $1m). In the absence of specific market
data, these unlisted investments are held at fair value based on
the cost of investment and adjusted as necessary for impairments
and revaluations on new funding rounds, which are seen to
approximate the fair value. All other fair value gains and/or
losses that are presented in Net gains on equity investments
measured at fair value through other comprehensive income in the
Condensed consolidated statement of comprehensive income for the
three months ended 31 March 2024 are Level 1 fair value
measurements, valued based on quoted prices in active
markets.
Financial instruments measured at fair value include $1,605m of
other investments, $5,504m held in money-market funds and $81m of
derivatives as at 31 March 2024. With the exception of derivatives
being Level 2 fair valued, and certain equity investments of $320m
categorised as Level 3, the aforementioned balances are Level 1
fair valued. Financial instruments measured at amortised cost
include $136m of cash collateral pledged to counterparties. The
total fair value of interest-bearing loans and borrowings at 31
March 2024, which have a carrying value of $34,551m in the
Condensed consolidated statement of financial position, was
$33,364m.
Table 22:
Financial instruments - contingent
consideration
|
|
|
2024
|
|
2023
|
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
1,945
|
192
|
2,137
|
2,222
|
|
Additions through business combinations
|
|
-
|
54
|
54
|
60
|
|
Settlements
|
|
(221)
|
(1)
|
(222)
|
(214)
|
|
Revaluations
|
|
-
|
16
|
16
|
-
|
|
Discount unwind
|
|
26
|
2
|
28
|
33
|
|
At 31 March
|
|
1,750
|
263
|
2,013
|
2,101
|
Contingent consideration arising from business combinations is fair
valued using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The contingent consideration balance relating to BMS's share of the
global diabetes alliance of $1,750m (31 December 2023:
$1,945m) would increase/decrease by $175m with an increase/decrease
in sales of 10%, as compared with the current
estimates.
Note 5: Business combinations
The acquisition of Gracell Biotechnologies, Inc. completed on 22
February 2024 and was recorded as a business combination using the
acquisition method of accounting in accordance with IFRS 3
'Business Combinations'. Consequently the assets acquired, and
liabilities assumed are recorded at fair value. Given the proximity
of the completion of the transaction to the reporting date, the
identification and determination of the fair values related to the
acquired balance sheet is on-going. This exercise is expected to
complete in Q2 2024 with the majority of the fair value expected to
be allocated to the intangible assets, as currently reported. The
upfront cash portion of the consideration represents a transaction
value of approximately $1.0bn. Combined, the upfront and potential
contingent value payments if achieved, represent, a transaction
value of approximately $1.2bn. The cash and cash equivalents
acquired on Gracell's balance sheet, totalled to $209m at the close
of the transaction.
Note 6: Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered
typical to its business, including litigation and investigations,
including Government investigations, relating to product liability,
commercial disputes, infringement of intellectual property (IP) rights, the validity of certain
patents, anti-trust law and sales and marketing
practices. The
matters discussed below constitute the more significant
developments since publication of the disclosures concerning legal
proceedings in the Company's Annual Report and Form 20-F
Information 2023 (the Disclosures). Information about the nature
and facts of the cases is disclosed in accordance with IAS
37.
As discussed in the Disclosures, the majority of claims involve
highly complex issues. Often these issues are subject to
substantial uncertainties and, therefore, the probability of a
loss, if any, being sustained and/or an estimate of the amount of
any loss is difficult to ascertain.
In cases that have been settled or adjudicated, or where
quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able
to make a reasonable estimate of the loss, AstraZeneca records the
loss absorbed or makes a provision for its best estimate of the
expected loss. The position could change over time and the
estimates that the Company made, and upon which the Company have
relied in calculating these provisions are inherently imprecise.
There can, therefore, be no assurance that any losses that result
from the outcome of any legal proceedings will not exceed the
amount of the provisions that have been booked in the accounts. The
major factors causing this uncertainty are described more fully in
the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and
enforce, its IP.
Matters disclosed in respect of the first quarter of 2024 and to 25
April 2024
Patent litigation
Legal proceedings brought against AstraZeneca considered to be
contingent liabilities
Forxiga
UK patent proceedings
In the UK, one of AstraZeneca's patents relating
to Forxiga is being challenged by Generics (UK)
Limited, Teva Pharmaceutical Industries Limited, and Glenmark
Pharmaceuticals Europe Limited. Trial is scheduled for March
2025.
Tagrisso
US patent proceedings
In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC
(Wyeth) filed a patent infringement lawsuit in the US District
Court for the District of Delaware (District Court) against
AstraZeneca relating to Tagrisso. In March 2024, the District Court dismissed
Puma. A trial, with Wyeth as the plaintiff, has been scheduled for
May 2024.
Legal proceedings brought by AstraZeneca considered to be
contingent assets
Calquence
US patent proceedings
In February 2022, in response to Paragraph IV notices from multiple
ANDA filers, AstraZeneca filed patent infringement lawsuits in the
US District Court for the District of Delaware (District Court). In
its complaint, AstraZeneca alleged that a generic version
of Calquence capsules, if approved and marketed, would
infringe patents that are owned or licensed by AstraZeneca. Trial
is scheduled for March 2025.
In March and April 2024, AstraZeneca entered into settlement
agreements with generic manufacturers, Sandoz Inc., and Natco
Pharma Limited with Natco Pharma Inc., resulting in dismissal of
the corresponding Calquence capsule ANDA litigation proceedings.
Additional Calquence capsule ANDA litigation proceedings with the
remaining three generic manufacturers are ongoing in the District
Court.
In April 2024, AstraZeneca received a Paragraph IV notice from an
ANDA filer relating to patents listed in the FDA Orange Book with
reference to Calquence tablets. AstraZeneca is considering its
response.
Lokelma
US patent proceedings
In August 2022, in response to Paragraph IV notices, AstraZeneca
initiated ANDA litigation against multiple generic filers in the US
District Court for the District of Delaware (District Court). Trial
is scheduled for March 2025.
AstraZeneca entered into a settlement agreement with a generic
manufacturer, Alkem Laboratories, which resulted in dismissal of
the corresponding litigation. Additional proceedings with the
remaining generic manufacturers are ongoing in the District
Court.
Soliris
US patent proceedings
In January 2024, Alexion initiated patent infringement litigation
against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court
for the District of Delaware alleging that Samsung's
biosimilar eculizumab product, for which Samsung is currently
seeking FDA approval, will infringe six Soliris-related patents. No trial date has been
scheduled. Five of the six asserted patents are also the subject
of inter
partes review proceedings
before the US Patent and Trademark Office. In February 2024,
Alexion filed a motion for a preliminary injunction seeking to
enjoin Samsung from launching its
biosimilar eculizumab product upon FDA approval. A hearing on
Alexion's preliminary injunction motion is scheduled for May
2024.
European patent proceedings
In March 2024, Alexion filed motions for preliminary injunctions
against Amgen and Samsung at the Hamburg Local Division of the
Unified Patent Court on the basis that Amgen's and Samsung's
biosimilar eculizumab products infringe
Alexion's eculizumab molecule patent that is expected to grant in
Q2 2024. No hearing date for the preliminary injunction motions has
been set.
Tagrisso
Russia patent proceedings
In Russia, in August 2023, AstraZeneca filed lawsuits in the
Arbitration Court of the Moscow Region (Court) against the Ministry
of Health of the Russian Federation and Axelpharm LLC (Axelpharm)
related to Axelpharm's improper use of AstraZeneca's information to
obtain authorisation to market a generic version
of Tagrisso. In December 2023, the Court dismissed the
lawsuit against the Ministry of Health of the Russian Federation.
In January 2024, AstraZeneca filed an appeal, and the appellate
court affirmed the dismissal in March 2024. The lawsuit against
Axelpharm remains pending.
In Russia, in November 2023, Axelpharm filed a compulsory licensing
action against AstraZeneca in the Court related to a patent that
covers Tagrisso. The compulsory licensing action remains
pending.
Product liability litigation
Legal proceedings brought against AstraZeneca for which a provision
has been taken
Nexium and Losec/Prilosec
US proceedings
AstraZeneca has been defending lawsuits brought in federal and
state courts involving claims that plaintiffs have been diagnosed
with various injuries following treatment with proton pump
inhibitors (PPIs), including Nexium and Prilosec. Most of the lawsuits alleged kidney injury. In
August 2017, the pending federal court cases were consolidated into
a multidistrict litigation (MDL) proceeding in the US District
Court for the District of New Jersey for pre-trial purposes. Cases
alleging kidney injury were also filed in Delaware and New Jersey
state courts.
In addition, AstraZeneca has been defending lawsuits involving
allegations of gastric cancer following treatment with PPIs,
including one such claim in the US District Court for the Middle
District of Louisiana (Louisiana District Court).
In October 2023, AstraZeneca resolved all pending claims in the
MDL, as well as all pending claims in Delaware and New Jersey state
courts, for $425M, for which a provision has been taken. The only
remaining case is the one pending in the Louisiana District Court,
which is scheduled for trial in January 2025.
Canada proceedings
In Canada, in July and August 2017, AstraZeneca was served with
three putative class action lawsuits. Two of the lawsuits have been
dismissed, one in 2019 and one in 2021. The third lawsuit seeks
authorisation to represent individual residents in Canada who
allegedly suffered kidney injuries from the use of proton pump
inhibitors, including Nexium and Losec.
Legal proceedings brought against AstraZeneca considered to be
contingent liabilities
Onglyza and Kombiglyze
US proceedings
In the US, AstraZeneca has been defending various lawsuits in both
California state court and in a consolidated federal proceeding
alleging heart failure, cardiac injuries, and/or death from
treatment with Onglyza or Kombiglyze. In the California state court proceeding, the
trial court granted summary judgment for AstraZeneca, which the
California appellate court affirmed. The California Supreme Court
has declined further review, and the California matter has
concluded. The consolidated federal cases were dismissed in August
2022 by the US District Court for the Eastern District of Kentucky.
That dismissal was affirmed by the US Court of Appeals for the
Sixth Circuit in February 2024.
Vaxzevria
UK proceedings
AstraZeneca is defending lawsuits in the UK involving multiple
claimants alleging injuries following vaccination with
AstraZeneca's COVID-19 vaccine. Most of the lawsuits involve claims
of thrombosis with thrombocytopenia syndrome. No trial dates have
been scheduled.
Commercial litigation
Legal proceedings brought against AstraZeneca considered to be
contingent liabilities
340B Antitrust Litigation
US proceedings
In September 2021, AstraZeneca was served with a class-action
antitrust complaint filed in the US District Court for the Western
District of New York (District Court) by Mosaic Health alleging a
conspiracy to restrict access to 340B discounts in the diabetes
market through contract pharmacies. In September 2022, the District
Court granted AstraZeneca's motion to dismiss the Complaint. In
February 2024, the District Court denied Plaintiffs' request to
file an amended complaint and entered an order closing the matter.
In March 2024, Plaintiffs filed an appeal.
Definiens
Germany proceedings
In Germany, in July 2020, AstraZeneca received a notice of
arbitration filed with the German Institution of Arbitration from
the sellers of Definiens AG (the Sellers) regarding the 2014 Share
Purchase Agreement (SPA) between AstraZeneca and the Sellers. The
Sellers claim that they are owed approximately $140m in earn-outs
under the SPA. In December 2023, after an arbitration
hearing, the arbitration panel made a final award of $46.43m in
favour of the Sellers. In March 2024, AstraZeneca filed an
application with the Bavarian Supreme Court to set aside the
arbitration award.
Legal proceedings brought by AstraZeneca considered to be
contingent assets
PARP Inhibitor Royalty Dispute
UK proceedings
In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline
plc, (GSK)) entered into two worldwide, royalty-bearing patent
license agreements with AstraZeneca related to GSK's
product niraparib. In May 2021, AstraZeneca filed a lawsuit against
GSK in the Commercial Court of England and Wales alleging that GSK
had failed to pay all of the royalties due
on niraparib sales under the license agreements. In
April 2023, after trial, the trial court issued a decision in
AstraZeneca's favour. In February 2024, Court of Appeal reversed.
In March 2024, AstraZeneca filed a request for permission to appeal
with the Supreme Court of the United Kingdom.
Government investigations/proceedings
Legal proceedings brought against AstraZeneca considered to be
contingent liabilities
340B Qui Tam
US proceedings
In July 2023, AstraZeneca was served with an unsealed civil lawsuit
brought by a qui tam relator on behalf of the United States,
several states, and the District of Columbia in the US District
Court for the Central District of California (District Court). The
complaint alleges that AstraZeneca violated the US False Claims Act
and state law analogues. In March 2024, the District Court granted
AstraZeneca's motion to dismiss the First Amended Complaint without
leave to amend. In April 2024, the relator filed an
appeal.
Legal proceedings brought by AstraZeneca considered to be
contingent assets
Inflation Reduction Act Litigation
US proceedings
In August 2023, AstraZeneca filed a lawsuit in the US District
Court for the District of Delaware (District Court) against the US
Department of Health and Human Services (HHS) challenging aspects
of the drug price negotiation provisions of the Inflation Reduction
Act and the implementing guidance and regulations. In March 2024,
the District Court granted HHS' motions and dismissed AstraZeneca's
lawsuit.
Arkansas 340B Litigation
US proceedings
In March 2024, AstraZeneca filed a lawsuit against the State of
Arkansas alleging that the Arkansas's 340B statute is pre-empted by
federal law and unconstitutional.
Other
Additional government inquiries
As is true for most, if not all, major prescription pharmaceutical
companies, AstraZeneca is currently involved in multiple inquiries
into drug marketing and pricing practices. In addition to the
investigations described above, various law enforcement offices
have, from time to time, requested information from the Group.
There have been no material developments in those
matters.
Note 7
Table 23: Q1 2024 - Product Sales year-on-year
analysis[13]
|
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
4,760
|
21
|
24
|
2,084
|
22
|
1,202
|
24
|
33
|
953
|
26
|
23
|
521
|
6
|
16
|
|
Tagrisso
|
1,595
|
12
|
15
|
623
|
20
|
488
|
10
|
17
|
302
|
18
|
15
|
182
|
(10)
|
(2)
|
|
Imfinzi
|
1,113
|
29
|
33
|
582
|
19
|
129
|
59
|
83
|
232
|
43
|
40
|
170
|
31
|
45
|
|
Calquence
|
718
|
35
|
35
|
494
|
29
|
39
|
n/m
|
n/m
|
153
|
42
|
39
|
32
|
44
|
47
|
|
Lynparza
|
705
|
8
|
11
|
288
|
7
|
167
|
23
|
33
|
191
|
7
|
5
|
59
|
(13)
|
(6)
|
|
Enhertu
|
122
|
n/m
|
n/m
|
-
|
-
|
83
|
n/m
|
n/m
|
26
|
n/m
|
n/m
|
13
|
n/m
|
n/m
|
|
Zoladex
|
276
|
22
|
28
|
3
|
9
|
214
|
28
|
35
|
35
|
9
|
6
|
24
|
(1)
|
7
|
|
Imjudo
|
62
|
67
|
70
|
39
|
22
|
4
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
11
|
n/m
|
n/m
|
|
Truqap
|
50
|
n/m
|
n/m
|
50
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Orpathys
|
12
|
48
|
53
|
-
|
-
|
12
|
48
|
53
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
107
|
(24)
|
(19)
|
5
|
(10)
|
66
|
(24)
|
(20)
|
6
|
(52)
|
(53)
|
30
|
(16)
|
(7)
|
|
BioPharmaceuticals: CVRM
|
3,012
|
19
|
22
|
748
|
20
|
1,365
|
17
|
24
|
716
|
29
|
26
|
183
|
(2)
|
7
|
|
Farxiga
|
1,845
|
42
|
45
|
473
|
60
|
711
|
43
|
50
|
553
|
41
|
37
|
108
|
(4)
|
5
|
|
Brilinta
|
323
|
(3)
|
(1)
|
163
|
(9)
|
88
|
9
|
21
|
67
|
(1)
|
(3)
|
5
|
(17)
|
(14)
|
|
Crestor
|
297
|
(3)
|
2
|
10
|
(32)
|
241
|
-
|
4
|
12
|
(26)
|
(27)
|
34
|
2
|
11
|
|
Seloken/Toprol-XL
|
165
|
(8)
|
(2)
|
-
|
(96)
|
161
|
(7)
|
(2)
|
3
|
(23)
|
(23)
|
1
|
(39)
|
(36)
|
|
Lokelma
|
114
|
16
|
19
|
52
|
(7)
|
21
|
83
|
90
|
18
|
60
|
56
|
23
|
16
|
29
|
|
roxadustat
|
75
|
24
|
28
|
-
|
-
|
75
|
24
|
28
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa
|
47
|
5
|
6
|
20
|
(3)
|
1
|
n/m
|
n/m
|
18
|
24
|
21
|
8
|
(14)
|
(4)
|
|
Wainua
|
5
|
n/m
|
n/m
|
5
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
141
|
(33)
|
(31)
|
25
|
(55)
|
67
|
(32)
|
(27)
|
45
|
(11)
|
(12)
|
4
|
3
|
5
|
|
BioPharmaceuticals: R&I
|
1,804
|
14
|
16
|
737
|
19
|
588
|
10
|
16
|
330
|
13
|
11
|
149
|
6
|
11
|
|
Symbicort
|
769
|
12
|
14
|
299
|
28
|
253
|
11
|
18
|
142
|
(3)
|
(6)
|
75
|
(5)
|
(3)
|
|
Fasenra
|
358
|
6
|
6
|
210
|
4
|
22
|
53
|
61
|
93
|
6
|
4
|
33
|
(6)
|
-
|
|
Pulmicort
|
224
|
2
|
5
|
5
|
(52)
|
191
|
5
|
9
|
20
|
-
|
(3)
|
8
|
(7)
|
(4)
|
|
Breztri
|
219
|
52
|
54
|
105
|
30
|
70
|
83
|
91
|
30
|
97
|
93
|
14
|
43
|
53
|
|
Tezspire
|
43
|
n/m
|
n/m
|
-
|
-
|
2
|
n/m
|
n/m
|
27
|
n/m
|
n/m
|
14
|
n/m
|
n/m
|
|
Saphnelo
|
91
|
94
|
95
|
83
|
89
|
1
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
3
|
80
|
99
|
|
Airsupra
|
7
|
n/m
|
n/m
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Others
|
93
|
(30)
|
(29)
|
28
|
(41)
|
49
|
(30)
|
(27)
|
14
|
3
|
1
|
2
|
(17)
|
(15)
|
|
BioPharmaceuticals: V&I
|
212
|
(40)
|
(40)
|
27
|
n/m
|
90
|
(13)
|
(12)
|
74
|
(27)
|
(26)
|
21
|
(87)
|
(86)
|
|
Synagis
|
171
|
(13)
|
(13)
|
(1)
|
76
|
90
|
16
|
18
|
61
|
(25)
|
(27)
|
21
|
(46)
|
(43)
|
|
Beyfortus
|
26
|
n/m
|
n/m
|
26
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
FluMist
|
7
|
n/m
|
n/m
|
2
|
n/m
|
-
|
59
|
59
|
5
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
|
COVID-19 mAbs
|
2
|
(99)
|
(99)
|
-
|
-
|
-
|
n/m
|
n/m
|
2
|
(53)
|
(56)
|
-
|
n/m
|
n/m
|
|
Others
|
6
|
(79)
|
(80)
|
-
|
-
|
-
|
n/m
|
n/m
|
6
|
(42)
|
(43)
|
-
|
-
|
-
|
|
Rare Disease
|
2,096
|
12
|
16
|
1,207
|
10
|
251
|
45
|
73
|
401
|
4
|
1
|
237
|
12
|
21
|
|
Ultomiris
|
859
|
32
|
34
|
482
|
27
|
32
|
n/m
|
n/m
|
202
|
27
|
24
|
143
|
46
|
61
|
|
Soliris
|
739
|
(11)
|
(8)
|
411
|
(8)
|
125
|
9
|
37
|
142
|
(22)
|
(24)
|
61
|
(30)
|
(28)
|
|
Strensiq
|
313
|
20
|
21
|
246
|
20
|
21
|
44
|
67
|
24
|
15
|
12
|
22
|
4
|
14
|
|
Koselugo
|
132
|
68
|
82
|
46
|
13
|
59
|
n/m
|
n/m
|
18
|
72
|
69
|
9
|
n/m
|
n/m
|
|
Kanuma
|
53
|
30
|
35
|
22
|
13
|
14
|
n/m
|
n/m
|
15
|
19
|
18
|
2
|
(3)
|
2
|
|
Other medicines
|
293
|
(6)
|
1
|
24
|
(33)
|
206
|
-
|
11
|
29
|
31
|
30
|
34
|
(31)
|
(25)
|
|
Nexium
|
240
|
(2)
|
7
|
22
|
(27)
|
172
|
10
|
23
|
13
|
13
|
11
|
33
|
(30)
|
(24)
|
|
Others
|
53
|
(23)
|
(21)
|
2
|
(63)
|
34
|
(31)
|
(29)
|
16
|
52
|
52
|
1
|
(53)
|
(49)
|
|
Total Product Sales
|
12,177
|
15
|
18
|
4,827
|
19
|
3,702
|
18
|
26
|
2,503
|
18
|
16
|
1,145
|
(7)
|
1
|
Table 24:
Alliance Revenue
|
|
|
Q1 2024
|
Q1 2023
|
|
|
|
$m
|
$m
|
|
Enhertu
|
|
339
|
220
|
|
Tezspire
|
|
77
|
43
|
|
Beyfortus
|
|
20
|
-
|
|
Other Alliance Revenue
|
|
21
|
23
|
|
Total
|
|
457
|
286
|
Table 25:
Collaboration Revenue
|
|
|
Q1 2024
|
Q1 2023
|
|
|
|
$m
|
$m
|
|
Farxiga: sales
milestones
|
|
45
|
24
|
|
Other Collaboration Revenue
|
|
-
|
3
|
|
Total
|
|
45
|
27
|
Table 26:
Other operating income and expense
|
|
|
Q1 2024
|
Q1 2023
|
|
|
|
$m
|
$m
|
|
brazikumab licence termination funding
|
|
-
|
38
|
|
Divestment of US rights to Pulmicort Flexhaler
|
|
-
|
241
|
|
Other
|
|
67
|
100
|
|
Total
|
|
67
|
379
|
Other shareholder
information
Financial calendar
Announcement of H1 and Q2 2024
results:
25 July 2024
Announcement of 9M and Q3 2024
results:
12 November 2024
Dividends are normally paid as follows:
First interim: announced with the half
year results and paid in September
Second interim: announced with full year results and paid in
March
Contacts
For details on how to contact the Investor Relations Team,
please click
here. For Media
contacts, click
here.
Addresses for correspondence
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
|
db@astfinancial.com
|
Trademarks
Trademarks of the AstraZeneca group of companies appear throughout
this document in italics. Medical publications also appear
throughout the document in italics. AstraZeneca, the AstraZeneca
logotype and the AstraZeneca symbol are all trademarks of the
AstraZeneca group of companies. Trademarks of companies other than
AstraZeneca that appear in this document
include: FasT CAR owned by Gracell
Biotechnology, Co., Ltd.; Plendil owned by AstraZeneca or Glenwood
GmbH (depending on geography); Beyfortus, a trademark of Sanofi Pasteur
Inc.; Enhertu, a trademark of Daiichi
Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd
(depending on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan
Biovitrum AB (publ). (depending on
geography); and Tezspire, a trademark of Amgen, Inc.
Information on or accessible through AstraZeneca's websites,
including astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act of
1995, AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This document contains certain forward-looking statements with
respect to the operations, performance and financial condition of
the Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
‒ the
risk of failure or delay in delivery of pipeline or launch of
new medicines
‒ the
risk of failure to meet regulatory or ethical requirements for
medicine development or approval
‒ the
risk of failures or delays in the quality or execution of the
Group's commercial strategies
‒ the
risk of pricing, affordability, access and
competitive pressures
‒ the
risk of failure to maintain supply of compliant,
quality medicines
‒ the
risk of illegal trade in the
Group's medicines
‒ the
impact of reliance on third-party goods
and services
‒ the
risk of failure in information technology
or cybersecurity
‒ the
risk of failure of critical processes
‒ the
risk of failure to collect and manage data in line with legal and
regulatory requirements and
strategic objectives
‒ the
risk of failure to attract, develop, engage and retain a diverse,
talented and capable workforce
‒ the
risk of failure to meet regulatory or ethical expectations on
environmental impact, including
climate change
‒ the
risk of the safety and efficacy of marketed medicines
being questioned
‒ the
risk of adverse outcome of litigation and/or
governmental investigations
‒ intellectual
property-related risks to the
Group's products
‒ the
risk of failure to achieve strategic plans or meet targets
or expectations
‒ the
risk of failure in financial control or the occurrence
of fraud
‒ the
risk of unexpected deterioration in the Group's
financial position
‒ the
impact that global and/or geopolitical events may have or continue
to have on these risks, on the Group's ability to continue to
mitigate these risks, and on the Group's operations, financial
results or financial condition
There can be no guarantees that the conditions to the closing of
the proposed transaction with Fusion will be satisfied on the
expected timetable or at all or that "FPI-2265" (Ac225-PSMA
I&T) or any combination product will receive the necessary
regulatory approvals or prove to be commercially successful if
approved. There can be no guarantees that the conditions to the
closing of the proposed transaction with Amolyt Pharma will be
satisfied on the expected timetable or at all or that eneboparatide
("AZP-3601") will receive the necessary regulatory approvals or
prove to be commercially successful if approved.
Glossary
1L,
2L,
etc
First line, second line, etc
ADC
Antibody drug conjugate
aHUS
Atypical haemolytic uraemic syndrome
AKT
Protein kinase B
AL
amyloidosis
Light chain amyloidosis
ANDA
Abbreviated New Drug Application (US)
ASO
Antisense oligonucleotide
ATTR-CM
Transthyretin-mediated amyloid cardiomyopathy
ATTRv
/ -PN / -CM Hereditary
transthyretin-mediated amyloid / polyneuropathy /
cardiomyopathy
BCMA
B-cell maturation antigen
BRCA
/
m
Breast cancer gene / mutation
BTC
Biliary tract cancer
BTK
Bruton tyrosine kinase
C5
Complement component 5
CAR-T
Chimeric antigen receptor T-cell
cCRT
Concurrent chemoradiotherapy
CD19
A gene expressed in B-cells
CER
Constant exchange rates
CHMP
Committee for Medicinal Products for Human Use (EU)
CI
Confidence interval
CKD
Chronic kidney disease
CLL
Chronic lymphocytic leukaemia
COPD
Chronic obstructive pulmonary disease
COP28 28th
annual United Nations (UN) climate meeting
CRC
Colorectal cancer
CRL
Compete Response Letter
CRPC
Castration-resistant prostate cancer
CSPC
Castration-sensitive prostate cancer
CTLA-4
Cytotoxic T-lymphocyte-associated antigen 4
CVRM
Cardiovascular, Renal and Metabolism
DDR
DNA damage response
DNA
Deoxyribonucleic acid
EBITDA
Earnings before interest, tax, depreciation and
amortisation
EGFR
/
m
Epidermal growth factor receptor / mutation
EGPA
Eosinophilic granulomatosis with polyangiitis
EPS
Earnings per
share
ERBB2
v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue
2
EVH
Extravascular haemolysis
FDA
Food and Drug Agency (US)
FDC
Fixed dose combination
g
Germline, e.g. gBRCAm
GAAP
Generally Accepted Accounting Principles
GEJ
Gastro oesophageal junction
GI
Gastrointestinal
GLP1
/
-RA
Glucagon-like peptide-1 / receptor agonist
gMG
Generalised myasthenia gravis
HCC
Hepatocellular carcinoma
HER2
/ +/- / low / m Human epidermal growth factor receptor
2 / positive / negative / low level expression /
mutant
HF/
pEF / rEF
Heart failure / with preserved ejection fraction / with reduced
ejection fraction
hMPV
Human metapneumovirus
HR
/ + /
-
Hormone receptor / positive / negative
HRD
Homologous recombination deficiency
HRRm
Homologous recombination repair gene mutation
i.m.
Intramuscular injection
i.v.
Intravenous injection
IAS
/
B
International Accounting Standards / Board
ICS
Inhaled corticosteroid
IFRS
International Financial Reporting Standards
IgAN
Immunoglobulin A neuropathy
IHC
Immunohistochemistry
IL-5,
IL-33,
etc
Interleukin-5, Interleukin-33, etc
IP
Intellectual Property
IVIg
Intravenous immune globulin
LABA
Long-acting beta-agonist
LAMA
Long-acting muscarinic-agonist
LS-SCLC
Limited stage small cell lung cancer
LRTD
Lower respiratory tract disease
m
Metastatic, e.g. mBTC , mCRPC, mCSPC
mAb
Monoclonal antibody
MDL
Multidistrict litigation
MET
Mesenchymal epithelial transition
NF1-PN
Neurofibromatosis type 1 with plexiform neurofibromas
n/m
Not meaningful
NMOSD
Neuromyelitis optica spectrum disorder
NRDL
National reimbursement drug list
NSCLC
Non-small cell lung cancer
OECD
Organisation for Economic Co-operation and Development
OOI
Other operating income
ORR
Overall response rate
OS
Overall survival
PARP
/ i /
-1sel
Poly ADP ribose polymerase / inhibitor /-1 selective
pCR
Pathologic complete response
PCSK9
Proprotein convertase subtilisin/kexin type 9
PD
Progressive disease
PD-1
Programmed cell death protein 1
PD-L1
Programmed cell death ligand 1
PDUFA
Prescription Drug User Fee Act
PHSSR
Partnership for Health System Sustainability and
Resilience
PFS
Progression free survival
PIK3CA
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha
PMDI
Pressure metered dose inhaler
PNH
/
-EVH
Paroxysmal nocturnal haemoglobinuria / with extravascular
haemolysis
PPI
Proton pump inhibitors
PSR
Platinum sensitive relapse
PTEN
Phosphatase and tensin homologue
Q3W,
Q4W, etc
Every three weeks, every four weeks, etc
R&D
Research and development
R&I
Respiratory & Immunology
RSV
Respiratory syncytial virus
sBLA
Supplemental biologics license application (US)
SCLC
Small cell lung cancer
s.c.
Subcutaneous injection
SEA
Severe eosinophilic asthma
SEC
Securities Exchange Commission (US)
SG&A
Sales, general and administration
SGLT2
Sodium-glucose cotransporter 2
SLL
Small lymphocytic lymphoma
SMI
Sustainable Markets Initiative
SPA
Share Purchase Agreement
T2D
Type-2 diabetes
TACE
Transarterial chemoembolization
THP
A treatment regimen: docetaxel, trastuzumab and
pertuzumab
TNBC
Triple negative breast cancer
TNF
Tumour necrosis factor
TOP1
Topoisomerase I
TROP2
Trophoblast cell surface antigen 2
USPTO
US Patent and Trademark Office
V&I
Vaccines & Immune Therapies
VBP
Volume-based procurement
VLP
Virus like particle
- End of document -
[1] Constant exchange
rates. The differences between Actual Change and CER Change are due
to foreign exchange movements between periods in 2024 vs. 2023. CER
financial measures are not accounted for according to generally
accepted accounting principles (GAAP) because they remove the
effects of currency movements from Reported
results.
[2] Core financial
measures are adjusted to exclude certain items. The differences
between Reported and Core measures are primarily due to costs
relating to the amortisation of intangibles, impairments, legal
settlements and restructuring charges. A full reconciliation
between Reported EPS and Core EPS is provided in Table 11 in the
Financial performance section of this document.
[3] The calculation of
Reported and Core Product Sales Gross Margin excludes the impact of
Alliance Revenue and Collaboration Revenue.
[4] In Table 2, the plus
and minus symbols denote the directional impact of the item being
discussed, e.g. a '+' symbol next to a comment related to the
R&D expense indicates that the item resulted in an increase in
the R&D spend relative to the prior year.
[5] Income from disposals
of assets and businesses, where the Group does not retain a
significant ongoing economic interest, continue to be recorded in
Other operating income and expense in the Company's financial
statements.
[6] The presentation of
Table 4 has been updated to show Total Revenue by medicine, by
including Alliance Revenue and Collaboration Revenue within each
revenue figure. Previously, this table showed Product Sales for
each medicine and therapy area, and the Company's total Alliance
Revenue and Collaboration Revenue were shown as separate lines at
the bottom of the table.
[7] The presentation of
this table has been updated by removing the "Acquisition of
Alexion" column due to immateriality of items in this
category
[8] Based on best
prevailing assumptions around currency
profiles.
[9] Based on average daily
spot rates 1 Jan 2023 to 31 Dec 2023.
[10] Based on average
daily spot rates 1 Jan 2024 to 31 Mar 2024.
[11] Based on average
daily spot rates 1 Mar 2024 to 31 Mar 2024.
[12] Other currencies
include AUD, BRL, CAD, KRW and RUB.
[13] The table provides an
analysis of year-on-year Product Sales, with Actual and CER growth
rates reflecting year-on-year growth. Due to rounding, the sum of a
number of dollar values and percentages may not agree to
totals.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:25
April 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|